Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine



   metabolic syndrome x
  

Disease ID 440
Disease metabolic syndrome x
Definition
A combination of medical conditions that, when present, increase the risk of heart attack, stroke, and diabetes mellitus. It includes the following medical conditions: increased blood pressure, central obesity, abnormal cholesterol levels, and elevated fasting glucose.
Synonym
cardiovascular syndrome, metabolic
cardiovascular syndromes, metabolic
dysmetabolic syndrome x
insulin resistance syndrome
insulin resistance syndrome x
metabolic cardiovascular syndrome
metabolic syndrome
metabolic syndrome x (disorder)
metabolic syndrome x [disease/finding]
metabolic syndromes
metabolic x syndrome
reaven syndrome x
reaven's syndrome
syndrome metabolic
syndrome x (metabolic)
syndrome x insulin resistance
syndrome x, dysmetabolic
syndrome x, insulin resistance
syndrome x, metabolic
syndrome x, reaven
syndrome, metabolic cardiovascular
syndrome, metabolic x
x syndrome, metabolic
OMIM
DOID
ICD10
UMLS
C0524620
MeSH
SNOMED-CT
Comorbidity
UMLS | Disease | Sentences' Count(Total Sentences:297)
C0028754  |  obesity  |  300
C0011847  |  diabetes  |  158
C0020538  |  hypertension  |  114
C0042373  |  vascular disease  |  75
C0011860  |  type 2 diabetes  |  72
C0007222  |  cardiovascular disease  |  63
C0023895  |  liver disease  |  54
C0036341  |  schizophrenia  |  52
C0011849  |  diabetes mellitus  |  46
C0004153  |  atherosclerosis  |  37
C0010068  |  coronary artery disease  |  34
C0033860  |  psoriasis  |  34
C0011860  |  type 2 diabetes mellitus  |  25
C0032460  |  polycystic ovary syndrome  |  23
C0022658  |  kidney disease  |  23
C0520679  |  obstructive sleep apnea  |  22
C0011570  |  depression  |  22
C0028754  |  adiposity  |  22
C0022661  |  chronic kidney disease  |  22
C0042373  |  vascular diseases  |  21
C0037315  |  sleep apnea  |  21
C0018799  |  heart disease  |  21
C0740394  |  hyperuricemia  |  19
C0020459  |  hyperinsulinemia  |  18
C0032460  |  polycystic ovary  |  17
C0006142  |  breast cancer  |  16
C0010068  |  coronary heart disease  |  16
C0027051  |  myocardial infarction  |  16
C0007222  |  cardiovascular diseases  |  16
C0027051  |  myocardial infarct  |  16
C0003873  |  rheumatoid arthritis  |  16
C0005586  |  bipolar disorder  |  15
C0020456  |  hyperglycemia  |  13
C0003864  |  arthritis  |  12
C0018099  |  gout  |  12
C0022658  |  renal disease  |  11
C0018801  |  heart failure  |  11
C0242350  |  erectile dysfunction  |  11
C0019158  |  hepatitis  |  10
C0020676  |  hypothyroidism  |  9
C0024141  |  systemic lupus erythematosus  |  9
C0155626  |  acute myocardial infarction  |  9
C0376358  |  prostate cancer  |  9
C0409974  |  lupus erythematosus  |  8
C0003467  |  anxiety  |  8
C0271650  |  glucose intolerance  |  8
C0011854  |  type 1 diabetes  |  8
C0008350  |  gallstone  |  7
C0029408  |  osteoarthritis  |  7
C0019163  |  hepatitis b  |  6
C0042870  |  vitamin d deficiency  |  6
C0085580  |  essential hypertension  |  6
C0004096  |  asthma  |  6
C0042870  |  vitamin d defic  |  6
C0020443  |  hypercholesterolemia  |  6
C0019196  |  hepatitis c  |  6
C0020456  |  hyperglycaemia  |  6
C0031099  |  periodontitis  |  6
C0035579  |  hypovitaminosis d  |  5
C1561644  |  chronic kidney disease (ckd)  |  5
C0028756  |  morbid obesity  |  5
C0007113  |  rectal cancer  |  5
C0002395  |  alzheimer's disease  |  5
C0020619  |  hypogonadism  |  5
C0031090  |  periodontal disease  |  5
C0009402  |  colorectal cancer  |  5
C0442874  |  neuropathy  |  5
C0035309  |  retinopathy  |  4
C0149931  |  migraine  |  4
C0030305  |  pancreatitis  |  4
C0023890  |  cirrhosis  |  4
C0007570  |  coeliac disease  |  4
C0010068  |  coronary disease  |  4
C0002170  |  alopecia  |  4
C0392525  |  nephrolithiasis  |  4
C0008350  |  gallstones  |  4
C0600260  |  obstructive pulmonary disease  |  4
C0019204  |  hepatocellular carcinoma  |  4
C0001430  |  adenoma  |  4
C0024117  |  chronic obstructive pulmonary disease  |  4
C0085207  |  gestational diabetes  |  4
C0022658  |  nephropathy  |  4
C0020538  |  high blood pressure  |  4
C0023787  |  lipodystrophy  |  4
C0004936  |  mental disorders  |  4
C1384514  |  primary aldosteronism  |  3
C0020542  |  pulmonary hypertension  |  3
C0497327  |  dementia  |  3
C0011854  |  type 1 diabetes mellitus  |  3
C0018799  |  cardiac disease  |  3
C1510471  |  hypovitaminosis  |  3
C0040188  |  tic disorders  |  3
C0037315  |  sleep apnea syndrome  |  3
C0033953  |  sexual dysfunction  |  3
C0024115  |  pulmonary disease  |  3
C0878544  |  cardiomyopathy  |  3
C0264716  |  chronic heart failure  |  3
C0014544  |  epilepsy  |  3
C0149521  |  chronic pancreatitis  |  3
C0520679  |  obstructive sleep apnea syndrome  |  3
C0085207  |  gestational diabetes mellitus  |  3
C0476089  |  endometrial ca  |  3
C0032460  |  polycystic ovarian syndrome  |  3
C0003850  |  arteriosclerosis  |  3
C0003872  |  psoriatic arthritis  |  3
C1257763  |  overnutrition  |  3
C0679466  |  cognitive deficits  |  3
C0040053  |  thrombosis  |  3
C0037315  |  sleep apnoea  |  3
C0042373  |  vascular disorders  |  3
C0008350  |  cholelithiasis  |  3
C0032914  |  preeclampsia  |  3
C0242231  |  coronary stenosis  |  3
C0476089  |  endometrial cancer  |  3
C0042373  |  vascular disorder  |  3
C1302401  |  colorectal adenoma  |  3
C0007222  |  cardiovascular disorders  |  3
C0017168  |  gastroesophageal reflux  |  2
C0035435  |  rheumatic diseases  |  2
C0003864  |  inflammatory arthritis  |  2
C0024117  |  chronic obstructive pulmonary disease (copd)  |  2
C0206081  |  hyperandrogenism  |  2
C0024623  |  gastric cancer  |  2
C0008312  |  primary biliary cirrhosis  |  2
C0085096  |  peripheral vascular disease  |  2
C0023646  |  lichen planus  |  2
C0033975  |  psychosis  |  2
C0014868  |  esophagitis  |  2
C0022116  |  ischemia  |  2
C0031117  |  peripheral neuropathy  |  2
C0033975  |  psychotic disorder  |  2
C0282193  |  iron overload  |  2
C0159069  |  impaired glucose tolerance  |  2
C0013473  |  eating disorder  |  2
C0221002  |  primary hyperparathyroidism  |  2
C0003469  |  anxiety disorder  |  2
C0376545  |  hematologic malignancies  |  2
C0018802  |  congestive heart failure  |  2
C0020428  |  aldosteronism  |  2
C0017168  |  esophageal reflux  |  2
C0013537  |  eclampsia  |  2
C0022116  |  ischaemia  |  2
C0740394  |  hyperuricaemia  |  2
C0028756  |  severe obesity  |  2
C0023895  |  hepatic disease  |  2
C0007134  |  renal cell carcinoma  |  2
C0041696  |  major depression  |  2
C0008312  |  biliary cirrhosis  |  2
C0520679  |  obstructive sleep apnoea  |  2
C0011860  |  diabetes mellitus type 2  |  2
C0017168  |  oesophageal reflux  |  2
C0033975  |  psychotic disorders  |  2
C0033687  |  proteinuria  |  2
C0035435  |  rheumatic disease  |  2
C0037317  |  sleep disturbance  |  2
C0151744  |  ischaemic heart disease  |  2
C0022658  |  renal diseases  |  2
C0032285  |  pneumoniae  |  2
C0852949  |  arterial disease  |  2
C0000889  |  acanthosis nigricans  |  2
C0221765  |  chronic schizophrenia  |  2
C0022661  |  end-stage renal disease  |  2
C0007688  |  central retinal artery occlusion  |  1
C0085160  |  hidradenitis  |  1
C0035333  |  retinitis  |  1
C0085580  |  primary hypertension  |  1
C0520679  |  obstructive sleep apnoea syndrome  |  1
C0011633  |  dermatomyositis  |  1
C0037315  |  sleep apnoea syndrome  |  1
C0021831  |  intestinal diseases  |  1
C0154251  |  lipid disorders  |  1
C0017178  |  gastrointestinal disease  |  1
C0017178  |  gastrointestinal diseases  |  1
C0035078  |  renal failure  |  1
C0022661  |  chronic renal failure  |  1
C0796279  |  osa syndrome  |  1
C0221056  |  adult dermatomyositis  |  1
C0022661  |  end stage renal disease  |  1
C0035326  |  retinal vascular occlusion  |  1
C0021775  |  intermittent claudication  |  1
C1257763  |  overfed  |  1
C0011860  |  type ii diabetes  |  1
C0153452  |  gallbladder ca  |  1
C0162836  |  hidradenitis suppurativa  |  1
C0270549  |  generalized anxiety disorder  |  1
C0007570  |  celiac disease  |  1
C0014869  |  reflux esophagitis  |  1
C0271623  |  hypogonadotrophic hypogonadism  |  1
C0026848  |  muscular diseases  |  1
C0038436  |  posttraumatic stress disorder  |  1
C0920350  |  autoimmune thyroiditis  |  1
C0042769  |  virus infection  |  1
C1704436  |  peripheral arterial disease  |  1
C0016977  |  biliary disease  |  1
C0006625  |  cachexia  |  1
C0750952  |  biliary tract cancer  |  1
C0002871  |  anemia  |  1
C0598608  |  hyperhomocysteinemia  |  1
C0035334  |  retinitis pigmentosa  |  1
C0036337  |  schizoaffective disorder  |  1
C1527336  |  sjogren's syndrome  |  1
C1260873  |  aortic valve disease  |  1
C0011884  |  diabetic retinopathy  |  1
C0030807  |  pemphigus  |  1
C0014130  |  endocrine disease  |  1
C0349530  |  early gastric cancer  |  1
C0278678  |  metastatic renal cell carcinoma  |  1
C0040128  |  thyroid disease  |  1
C0022658  |  kidney diseases  |  1
C0023903  |  liver cancer  |  1
C0027868  |  neuromuscular diseases  |  1
C0342199  |  iodine deficiency  |  1
C0003128  |  anovulation  |  1
C0006012  |  borderline personality disorder  |  1
C0153452  |  gallbladder cancer  |  1
C0004943  |  behcet disease  |  1
C0022661  |  chronic renal disease  |  1
C0037274  |  skin disease  |  1
C0026848  |  myopathy  |  1
C0027765  |  nervous disorders  |  1
C0021831  |  intestinal disease  |  1
C0017551  |  gilbert's syndrome  |  1
C0917713  |  becker muscular dystrophy  |  1
C0023895  |  liver diseases  |  1
C0042133  |  uterine leiomyoma  |  1
C0017661  |  iga glomerulonephritis  |  1
C0018799  |  cardiac diseases  |  1
C0014038  |  brain inflammation  |  1
C0010054  |  coronary atherosclerosis  |  1
C0037280  |  infestation  |  1
C0037317  |  sleep disturbances  |  1
C0005283  |  beta thalassemia  |  1
C0003969  |  vitamin c deficiency  |  1
C0010481  |  cushing's syndrome  |  1
C0026769  |  multiple sclerosis  |  1
C0020538  |  hypertensive disease  |  1
C1565489  |  renal insufficiency  |  1
C0027708  |  nephroblastoma  |  1
C0039263  |  takayasu arteritis  |  1
C0020503  |  secondary hyperparathyroidism  |  1
C0149931  |  migraine headache  |  1
C0020443  |  hypercholesterolaemia  |  1
C0031090  |  periodontal diseases  |  1
C0085278  |  antiphospholipid syndrome  |  1
C0018799  |  heart diseases  |  1
C0037293  |  skin tags  |  1
C0026850  |  muscular dystrophy  |  1
C0005684  |  bladder cancer  |  1
C0013338  |  growth hormone deficiency  |  1
C0014130  |  endocrine disorders  |  1
C0028797  |  occupational diseases  |  1
C0007102  |  colon cancer  |  1
C0010276  |  craniopharyngioma  |  1
C0268425  |  alstrom syndrome  |  1
C0019204  |  hepatocarcinoma  |  1
C0027868  |  neuromuscular disease  |  1
C0031485  |  phenylketonuria  |  1
C0014733  |  erysipelas  |  1
C0021359  |  infertility  |  1
C0009241  |  cognitive disorders  |  1
C0030567  |  parkinson's disease  |  1
C0020538  |  increased blood pressure  |  1
C0003972  |  atherosclerotic cardiovascular disease  |  1
C0015190  |  sick euthyroid syndrome  |  1
C0041408  |  turner syndrome  |  1
C0031485  |  phenylketonuria (pku)  |  1
C0028797  |  occupational disease  |  1
C0008148  |  chlamydia  |  1
C0041696  |  major depressive disorder  |  1
C0001622  |  hypercortisolism  |  1
C0271650  |  prediabetes  |  1
C0007273  |  carotid artery disease  |  1
C0152025  |  polyneuropathy  |  1
C0018021  |  thyroid enlargement  |  1
C0015674  |  chronic fatigue syndrome  |  1
C0262428  |  collagen vascular disease  |  1
C0003873  |  rheumatoid disease  |  1
C0018023  |  nodular goiter  |  1
C0020676  |  hypothyroid  |  1
C0039730  |  thalassemia  |  1
C0259749  |  autonomic neuropathy  |  1
C0034885  |  rectal neoplasms  |  1
C0003469  |  anxiety disorders  |  1
C0017168  |  gastroesophageal reflux disease  |  1
C0038013  |  ankylosing spondylitis  |  1
C0020514  |  hyperprolactinemia  |  1
C0017601  |  glaucoma  |  1
C1332977  |  childhood leukemia  |  1
C0011880  |  diabetic ketoacidosis  |  1
C0751651  |  mitochondrial disease  |  1
C0011860  |  type ii diabetes mellitus  |  1
C0038436  |  post-traumatic stress disorder  |  1
C0151313  |  sensory neuropathy  |  1
C0035302  |  retinal artery occlusion  |  1
C0017168  |  esophageal reflux disease  |  1
C0029456  |  osteoporosis  |  1
C0151744  |  myocardial ischaemia  |  1
Curated Gene
Entrez_id | Symbol | Resource(Total Genes:42)
338  |  APOB  |  GWASCAT
3630  |  INS  |  CTD_human
3159  |  HMGA1  |  CTD_human
56729  |  RETN  |  CTD_human
5444  |  PON1  |  CTD_human
3358  |  HTR2C  |  CTD_human
4846  |  NOS3  |  CTD_human
8647  |  ABCB11  |  GWASCAT
10452  |  TOMM40  |  GWASCAT
23411  |  SIRT1  |  CTD_human
3569  |  IL6  |  CTD_human
1401  |  CRP  |  CTD_human
79068  |  FTO  |  GWASCAT
116519  |  APOA5  |  GWASCAT
19  |  ABCA1  |  GWASCAT
57818  |  G6PC2  |  GWASCAT
9415  |  FADS2  |  GWASCAT
283450  |  HECTD4  |  GWASCAT
79661  |  NEIL1  |  CTD_human
6347  |  CCL2  |  CTD_human
816  |  CAMK2B  |  GWASCAT
8882  |  ZPR1  |  GWASCAT
9370  |  ADIPOQ  |  CTD_human
4023  |  LPL  |  GWASCAT
7021  |  TFAP2B  |  GWASCAT
3929  |  LBP  |  CTD_human
23644  |  EDC4  |  GWASCAT
3606  |  IL18  |  CTD_human
1071  |  CETP  |  GWASCAT
746  |  TMEM258  |  GWASCAT
10062  |  NR1H3  |  GWASCAT
6934  |  TCF7L2  |  GWASCAT
6462  |  SHBG  |  CTD_human
2646  |  GCKR  |  GWASCAT
51085  |  MLXIPL  |  GWASCAT
3952  |  LEP  |  CTD_human
8856  |  NR1I2  |  CTD_human
9970  |  NR1I3  |  CTD_human
3992  |  FADS1  |  GWASCAT
84811  |  BUD13  |  GWASCAT
57761  |  TRIB3  |  CTD_human
2590  |  GALNT2  |  GWASCAT
Inferring Gene
Entrez_id | Symbol | Resource(Total Genes:217)
7124  |  TNF  |  CIPHER
19  |  ABCA1  |  CIPHER
368  |  ABCC6  |  CIPHER
6833  |  ABCC8  |  CIPHER
64241  |  ABCG8  |  CIPHER
32  |  ACACB  |  CIPHER
35  |  ACADS  |  CIPHER
1636  |  ACE  |  CIPHER
100  |  ADA  |  CIPHER
116  |  ADCYAP1  |  CIPHER
9370  |  ADIPOQ  |  CIPHER;CTD_human
51094  |  ADIPOR1  |  CIPHER
79602  |  ADIPOR2  |  CIPHER
151  |  ADRA2B  |  CIPHER
154  |  ADRB2  |  CIPHER
155  |  ADRB3  |  CIPHER
183  |  AGT  |  CIPHER
185  |  AGTR1  |  CIPHER
186  |  AGTR2  |  CIPHER
197  |  AHSG  |  CIPHER
11216  |  AKAP10  |  CIPHER
241  |  ALOX5AP  |  CIPHER
270  |  AMPD1  |  CIPHER
83854  |  ANGPTL6  |  CIPHER
308  |  ANXA5  |  CIPHER
337  |  APOA4  |  CIPHER
116519  |  APOA5  |  CIPHER
338  |  APOB  |  CIPHER
345  |  APOC3  |  CIPHER
348  |  APOE  |  CIPHER
367  |  AR  |  CIPHER
406  |  ARNTL  |  CIPHER
56938  |  ARNTL2  |  CIPHER
590  |  BCHE  |  CIPHER
718  |  C3  |  CIPHER
11132  |  CAPN10  |  CIPHER
6356  |  CCL11  |  CIPHER
6347  |  CCL2  |  CIPHER;CTD_human
959  |  CD40LG  |  CIPHER
1071  |  CETP  |  CIPHER
9575  |  CLOCK  |  CIPHER
1281  |  COL3A1  |  CIPHER
1361  |  CPB2  |  CIPHER
1408  |  CRY2  |  CIPHER
1442  |  CSH1  |  CIPHER
1443  |  CSH2  |  CIPHER
1511  |  CTSG  |  CIPHER
1524  |  CX3CR1  |  CIPHER
1585  |  CYP11B2  |  CIPHER
1813  |  DRD2  |  CIPHER
1906  |  EDN1  |  CIPHER
2006  |  ELN  |  CIPHER
5167  |  ENPP1  |  CIPHER
2099  |  ESR1  |  CIPHER
2100  |  ESR2  |  CIPHER
2152  |  F3  |  CIPHER
2166  |  FAAH  |  CIPHER
2168  |  FABP1  |  CIPHER
2169  |  FABP2  |  CIPHER
9415  |  FADS2  |  CIPHER
2222  |  FDFT1  |  CIPHER
2244  |  FGB  |  CIPHER
2339  |  FNTA  |  CIPHER
2342  |  FNTB  |  CIPHER
2303  |  FOXC2  |  CIPHER
79068  |  FTO  |  CIPHER
2730  |  GCLM  |  CIPHER
2689  |  GH2  |  CIPHER
2690  |  GHR  |  CIPHER
51738  |  GHRL  |  CIPHER
2693  |  GHSR  |  CIPHER
2701  |  GJA4  |  CIPHER
2739  |  GLO1  |  CIPHER
2784  |  GNB3  |  CIPHER
2876  |  GPX1  |  CIPHER
3162  |  HMOX1  |  CIPHER
11100  |  HNRNPUL1  |  CIPHER
3290  |  HSD11B1  |  CIPHER
3312  |  HSPA8  |  CIPHER
23463  |  ICMT  |  CIPHER
3416  |  IDE  |  CIPHER
10644  |  IGF2BP2  |  CIPHER
3484  |  IGFBP1  |  CIPHER
3586  |  IL10  |  CIPHER
3600  |  IL15  |  CIPHER
3601  |  IL15RA  |  CIPHER
3606  |  IL18  |  CIPHER;CTD_human
3552  |  IL1A  |  CIPHER
3553  |  IL1B  |  CIPHER
3667  |  IRS1  |  CIPHER
3689  |  ITGB2  |  CIPHER
3767  |  KCNJ11  |  CIPHER
3938  |  LCT  |  CIPHER
3949  |  LDLR  |  CIPHER
3952  |  LEP  |  CIPHER;CTD_human
3953  |  LEPR  |  CIPHER
3957  |  LGALS2  |  CIPHER
3984  |  LIMK1  |  CIPHER
3990  |  LIPC  |  CIPHER
4000  |  LMNA  |  CIPHER
7804  |  LRP8  |  CIPHER
4049  |  LTA  |  CIPHER
4048  |  LTA4H  |  CIPHER
8195  |  MKKS  |  CIPHER
4312  |  MMP1  |  CIPHER
4321  |  MMP12  |  CIPHER
4314  |  MMP3  |  CIPHER
4524  |  MTHFR  |  CIPHER
4565  |  MT-TI  |  CIPHER
8202  |  NCOA3  |  CIPHER
4846  |  NOS3  |  CIPHER;CTD_human
4862  |  NPAS2  |  CIPHER
4852  |  NPY  |  CIPHER
94233  |  OPN4  |  CIPHER
441933  |  OR13G1  |  CIPHER
64805  |  P2RY12  |  CIPHER
23022  |  PALLD  |  CIPHER
55486  |  PARL  |  CIPHER
5078  |  PAX4  |  CIPHER
5105  |  PCK1  |  CIPHER
5144  |  PDE4D  |  CIPHER
3651  |  PDX1  |  CIPHER
5174  |  PDZK1  |  CIPHER
5175  |  PECAM1  |  CIPHER
8864  |  PER2  |  CIPHER
5332  |  PLCB4  |  CIPHER
5444  |  PON1  |  CIPHER;CTD_human
5465  |  PPARA  |  CIPHER
5467  |  PPARD  |  CIPHER
5468  |  PPARG  |  CIPHER
10891  |  PPARGC1A  |  CIPHER
5506  |  PPP1R3A  |  CIPHER
5687  |  PSMA6  |  CIPHER
5740  |  PTGIS  |  CIPHER
5742  |  PTGS1  |  CIPHER
5743  |  PTGS2  |  CIPHER
56729  |  RETN  |  CIPHER;CTD_human
5997  |  RGS2  |  CIPHER
6098  |  ROS1  |  CIPHER
6401  |  SELE  |  CIPHER
5054  |  SERPINE1  |  CIPHER
376497  |  SLC27A1  |  CIPHER
6720  |  SREBF1  |  CIPHER
6721  |  SREBF2  |  CIPHER
6934  |  TCF7L2  |  CIPHER
7058  |  THBS2  |  CIPHER
8914  |  TIMELESS  |  CIPHER
7099  |  TLR4  |  CIPHER
23495  |  TNFRSF13B  |  CIPHER
57761  |  TRIB3  |  CIPHER;CTD_human
59286  |  UBL5  |  CIPHER
7350  |  UCP1  |  CIPHER
7351  |  UCP2  |  CIPHER
7352  |  UCP3  |  CIPHER
7391  |  USF1  |  CIPHER
10911  |  UTS2  |  CIPHER
7421  |  VDR  |  CIPHER
7422  |  VEGFA  |  CIPHER
7432  |  VIP  |  CIPHER
7434  |  VIPR2  |  CIPHER
79001  |  VKORC1  |  CIPHER
7466  |  WFS1  |  CIPHER
7486  |  WRN  |  CIPHER
10269  |  ZMPSTE24  |  CIPHER
8647  |  ABCB11  |  CIPHER
348158  |  ACSM2B  |  CIPHER
150  |  ADRA2A  |  CIPHER
217  |  ALDH2  |  CIPHER
335  |  APOA1  |  CIPHER
84811  |  BUD13  |  CIPHER
114902  |  C1QTNF5  |  CIPHER
84226  |  C2orf16  |  CIPHER
816  |  CAMK2B  |  CIPHER
79635  |  CCDC121  |  CIPHER
948  |  CD36  |  CIPHER
1012  |  CDH13  |  CIPHER
1149  |  CIDEA  |  CIPHER
1268  |  CNR1  |  CIPHER
1401  |  CRP  |  CIPHER;CTD_human
1576  |  CYP3A4  |  CIPHER
23644  |  EDC4  |  CIPHER
100128637  |  EEF1A1P26  |  CIPHER
57818  |  G6PC2  |  CIPHER
2590  |  GALNT2  |  CIPHER
2645  |  GCK  |  CIPHER
2646  |  GCKR  |  CIPHER
11321  |  GPN1  |  CIPHER
352961  |  HCG26  |  CIPHER
9709  |  HERPUD1  |  CIPHER
3356  |  HTR2A  |  CIPHER
3358  |  HTR2C  |  CIPHER;CTD_human
3569  |  IL6  |  CIPHER;CTD_human
3572  |  IL6ST  |  CIPHER
23175  |  LPIN1  |  CIPHER
4023  |  LPL  |  CIPHER
4041  |  LRP5  |  CIPHER
51085  |  MLXIPL  |  CIPHER
10062  |  NR1H3  |  CIPHER
79660  |  PPP1R3B  |  CIPHER
441726  |  RPL28P4  |  CIPHER
100271597  |  RPS3AP42  |  CIPHER
8170  |  SLC14A2  |  CIPHER
6532  |  SLC6A4  |  CIPHER
79689  |  STEAP4  |  CIPHER
7021  |  TFAP2B  |  CIPHER
10452  |  TOMM40  |  CIPHER
7168  |  TPM1  |  CIPHER
10221  |  TRIB1  |  CIPHER
84450  |  ZNF512  |  CIPHER
79661  |  NEIL1  |  CTD_human
3929  |  LBP  |  CTD_human
6462  |  SHBG  |  CTD_human
8856  |  NR1I2  |  CTD_human
9970  |  NR1I3  |  CTD_human
3159  |  HMGA1  |  CTD_human
3630  |  INS  |  CTD_human
23411  |  SIRT1  |  CTD_human
Text Mined Gene
Entrez_id | Symbol | Score | Resource(Total Genes:13)
9370  |  ADIPOQ  |  1.953  |  DISEASES
158833  |  AWAT1  |  2.799  |  DISEASES
1622  |  DBI  |  2.818  |  DISEASES
2641  |  GCG  |  1.743  |  DISEASES
8972  |  MGAM  |  1.033  |  DISEASES
4878  |  NPPA  |  1.096  |  DISEASES
387  |  RHOA  |  1.547  |  DISEASES
6319  |  SCD  |  1.259  |  DISEASES
6462  |  SHBG  |  1.82  |  DISEASES
11000  |  SLC27A3  |  3.55  |  DISEASES
6514  |  SLC2A2  |  1.048  |  DISEASES
6517  |  SLC2A4  |  2.539  |  DISEASES
7293  |  TNFRSF4  |  1.458  |  DISEASES
Locus(Waiting for update.)
Disease ID 440
Disease metabolic syndrome x
Integrated Phenotype(Waiting for update.)
Text Mined Phenotype
HPO | Name | Sentences' Count(Total Phenotypes:195)
HP:0001513  |  Obesity  |  318
HP:0000855  |  Insulin resistance  |  174
HP:0000822  |  Hypertension  |  117
HP:0001397  |  Hepatic steatosis  |  68
HP:0100753  |  Schizophrenia  |  54
HP:0000819  |  Diabetes mellitus  |  46
HP:0002621  |  Atherosclerosis  |  42
HP:0001677  |  Coronary artery disease  |  41
HP:0012743  |  Central obesity  |  38
HP:0003765  |  Psoriasis  |  36
HP:0010535  |  Sleep apnea  |  24
HP:0012622  |  Chronic kidney disease  |  23
HP:0000716  |  Depression  |  22
HP:0002870  |  Obstructive sleep apnea  |  22
HP:0002149  |  Hyperuricemia  |  22
HP:0000842  |  Elevated insulin level  |  21
HP:0002104  |  Absence of spontaneous respiration  |  20
HP:0001297  |  Cerebral vascular events  |  18
HP:0000147  |  Sclerocystic ovaries  |  18
HP:0003002  |  Breast carcinoma  |  17
HP:0001658  |  Myocardial infarction  |  17
HP:0001370  |  Rheumatoid arthritis  |  16
HP:0003077  |  Hyperlipidemia  |  15
HP:0007302  |  Bipolar disorder  |  15
HP:0002155  |  Increased triglycerides  |  14
HP:0001997  |  Gout  |  13
HP:0003074  |  High blood glucose  |  13
HP:0001635  |  Congestive heart failure  |  13
HP:0001369  |  Arthritis  |  12
HP:0000833  |  Glucose intolerance  |  12
HP:0001824  |  Weight loss  |  11
HP:0000802  |  Erectile dysfunction  |  11
HP:0100543  |  Cognitive deficits  |  11
HP:0012115  |  Liver inflammation  |  10
HP:0012125  |  Prostate cancer  |  10
HP:0200123  |  Chronic liver inflammation  |  10
HP:0002725  |  Systemic lupus erythematosus  |  9
HP:0012594  |  High urine albumin levels  |  9
HP:0000821  |  Underactive thyroid  |  9
HP:0000739  |  Anxiety  |  8
HP:0012592  |  Albuminuria  |  8
HP:0005110  |  Atrial fibrillation  |  8
HP:0000787  |  Renal calculi  |  7
HP:0002758  |  Osteoarthritis  |  7
HP:0001081  |  Gallstones  |  7
HP:0003281  |  Increased ferritin  |  6
HP:0003124  |  Elevated serum cholesterol  |  6
HP:0000704  |  Pyorrhea  |  6
HP:0002140  |  Ischemic stroke  |  6
HP:0002099  |  Asthma  |  6
HP:0100512  |  Vitamin D deficiency  |  6
HP:0000135  |  Hypogonadism  |  5
HP:0000112  |  Nephropathy  |  5
HP:0006510  |  Chronic obstructive pulmonary disease  |  5
HP:0001394  |  Hepatic cirrhosis  |  5
HP:0003774  |  End-stage renal failure  |  5
HP:0002664  |  Neoplasia  |  5
HP:0001268  |  Mental deterioration  |  5
HP:0030731  |  Carcinoma  |  5
HP:0001712  |  Left ventricular hypertrophy  |  5
HP:0008711  |  Benign prostatic hypertrophy  |  4
HP:0001596  |  Hair loss  |  4
HP:0001714  |  Ventricular hypertrophy  |  4
HP:0004943  |  Accelerated atherosclerosis  |  4
HP:0001733  |  Pancreatic inflammation  |  4
HP:0000166  |  Severe periodontal disease  |  4
HP:0000708  |  Behavioral problems  |  4
HP:0100602  |  Pre-eclampsia  |  4
HP:0000488  |  Noninflammatory retina disease  |  4
HP:0001402  |  Hepatocellular carcinoma  |  4
HP:0009125  |  Lipodystrophy  |  4
HP:0001395  |  Hepatic fibrosis  |  4
HP:0009800  |  gestational diabetes  |  4
HP:0003287  |  Abnormality of mitochondrial metabolism  |  4
HP:0012531  |  Pain  |  4
HP:0002076  |  Migraine headaches  |  4
HP:0001511  |  Prenatal onset growth retardation  |  4
HP:0000726  |  Dementia  |  3
HP:0001638  |  Cardiomyopathy  |  3
HP:0006280  |  Chronic pancreas inflammation  |  3
HP:0002910  |  Elevated transaminases  |  3
HP:0002315  |  Headaches  |  3
HP:0001518  |  Small for gestational age  |  3
HP:0001907  |  Thromboembolic disease  |  3
HP:0005202  |  Helicobacter pylori infection  |  3
HP:0002634  |  Arteriosclerosis  |  3
HP:0100033  |  Tic disorder  |  3
HP:0012378  |  Fatigue  |  3
HP:0002092  |  Pulmonary artery hypertension  |  3
HP:0005584  |  Renal cell carcinoma  |  2
HP:0012126  |  Gastric cancer  |  2
HP:0100633  |  Inflammation of the esophagus  |  2
HP:0004929  |  Coronary artherosclerosis  |  2
HP:0001717  |  Coronary artery calcification  |  2
HP:0000789  |  Infertility  |  2
HP:0001262  |  Somnolence  |  2
HP:0002591  |  Voracious appetite  |  2
HP:0002063  |  Muscle rigidity  |  2
HP:0001956  |  Centripetal obesity  |  2
HP:0040154  |  Hidradenitis suppurativa  |  2
HP:0000709  |  Psychosis  |  2
HP:0002721  |  Immunodeficiency  |  2
HP:0040213  |  Hypopnea  |  2
HP:0002148  |  Hypophosphataemia  |  2
HP:0040171  |  Low serum testosterone levels  |  2
HP:0001919  |  Acute renal failure  |  2
HP:0000083  |  Renal insufficiency  |  2
HP:0000956  |  Keratosis nigricans  |  2
HP:0002613  |  Biliary cirrhosis  |  2
HP:0008200  |  Primary hyperparathyroidism  |  2
HP:0009830  |  Peripheral neuritis  |  2
HP:0000093  |  Proteinuria  |  2
HP:0011675  |  Arrhythmias  |  2
HP:0003418  |  Back pain  |  2
HP:0002360  |  Sleep disturbance  |  2
HP:0005086  |  Knee osteoarthritis  |  2
HP:0003419  |  Low back pain  |  2
HP:0002020  |  Heartburn  |  2
HP:0002119  |  Ventricular dilatation  |  2
HP:0012075  |  Personality disorder  |  1
HP:0002896  |  Liver cancer  |  1
HP:0001410  |  Decreased liver function  |  1
HP:0000763  |  Sensory neuropathy  |  1
HP:0001055  |  Erysipelas  |  1
HP:0000138  |  Ovarian cyst  |  1
HP:0002500  |  Leukoaraiosis  |  1
HP:0000867  |  Secondary hyperparathyroidism  |  1
HP:0005994  |  Nodular goiter  |  1
HP:0003003  |  Colon cancer  |  1
HP:0012076  |  Borderline personality disorder  |  1
HP:0010609  |  Skin tags  |  1
HP:0001510  |  Growth deficiency  |  1
HP:0001324  |  Muscular weakness  |  1
HP:0000026  |  Decreased function of male gonad  |  1
HP:0011123  |  Skin inflammation  |  1
HP:0002667  |  Wilms tumor  |  1
HP:0002459  |  Dysautonomia  |  1
HP:0000824  |  Growth hormone deficiency  |  1
HP:0000939  |  Osteoporosis  |  1
HP:0100785  |  Insomnia  |  1
HP:0003560  |  Muscular dystrophy  |  1
HP:0000044  |  Hypogonadotrophic hypogonadism  |  1
HP:0003233  |  Low HDL-cholesterol  |  1
HP:0001578  |  Hypercortisolism  |  1
HP:0001250  |  Seizures  |  1
HP:0001050  |  Plethora  |  1
HP:0001974  |  Leukocytosis  |  1
HP:0008189  |  Insulin insensitivity  |  1
HP:0004417  |  Intermittent claudication  |  1
HP:0030062  |  Craniopharyngioma  |  1
HP:0001013  |  Eruptive xanthomas  |  1
HP:0004326  |  Cachexia  |  1
HP:0009725  |  Bladder neoplasm  |  1
HP:0006279  |  Beta-cell dysfunction  |  1
HP:0001271  |  Polyneuropathy  |  1
HP:0000501  |  Glaucoma  |  1
HP:0006349  |  Agenesis of permanent dentition  |  1
HP:0008672  |  Oxalate nephrolithiasis  |  1
HP:0001685  |  Myocardial fibrosis  |  1
HP:0003198  |  Myopathic changes  |  1
HP:0012213  |  Reduced creatinine clearance  |  1
HP:0001953  |  Diabetic ketosis  |  1
HP:0030828  |  Wheezing  |  1
HP:0030685  |  Decreased adiponectin level  |  1
HP:0002608  |  Celiac disease  |  1
HP:0004950  |  Peripheral artery disease  |  1
HP:0002925  |  Increased serum thyroid-stimulating hormone  |  1
HP:0002189  |  Excessive daytime sleepiness  |  1
HP:0001520  |  Birthweight > 90th percentile  |  1
HP:0100510  |  Vitamin C deficiency  |  1
HP:0002383  |  Encephalitis  |  1
HP:0000131  |  Uterine leiomyoma  |  1
HP:0001007  |  Hirsutism  |  1
HP:0005952  |  Decreased lung function  |  1
HP:0100601  |  Eclampsia  |  1
HP:0005978  |  Noninsulin dependent diabetes mellitus  |  1
HP:0001631  |  Atria septal defect  |  1
HP:0005181  |  Premature coronary artery disease  |  1
HP:0001263  |  Developmental retardation  |  1
HP:0001289  |  Confusion  |  1
HP:0000820  |  Thyroid abnormality  |  1
HP:0030833  |  Neck pain  |  1
HP:0000870  |  Hyperprolactinemia  |  1
HP:0040216  |  Hypoinsulinemia  |  1
HP:0000510  |  Retinitis pigmentosa  |  1
HP:0001943  |  Hypoglycemia  |  1
HP:0012432  |  Chronic fatigue  |  1
HP:0001061  |  Acne  |  1
HP:0001708  |  Impaired right ventricular function  |  1
HP:0001645  |  Sudden cardiac death  |  1
HP:0000020  |  Bladder incontinence  |  1
HP:0002960  |  Autoimmune condition  |  1
HP:0001903  |  Anemia  |  1
HP:0001681  |  Angina pectoris  |  1
HP:0000752  |  Hyperactive behavior  |  1
Disease ID 440
Disease metabolic syndrome x
Manually Symptom
UMLS  | Name(Total Manually Symptoms:2)
C0242339  |  dyslipidemia
C0042373  |  vascular disease
Text Mined Symptom
UMLS | Name | Sentences' Count(Total Symptoms:51)
C0011847  |  diabetes  |  161
C0020538  |  hypertension  |  113
C0042373  |  vascular disease  |  67
C0242339  |  dyslipidemia  |  66
C0007222  |  cardiovascular disease  |  57
C0023895  |  liver disease  |  54
C0015695  |  fatty liver  |  45
C0011849  |  diabetes mellitus  |  44
C0004153  |  atherosclerosis  |  41
C0010068  |  coronary artery disease  |  36
C0856169  |  endothelial dysfunction  |  28
C0022661  |  chronic kidney disease  |  23
C1393529  |  vascular complications  |  23
C0018799  |  heart disease  |  23
C0011570  |  depression  |  22
C0427008  |  stiffness  |  22
C0740394  |  hyperuricemia  |  20
C0311277  |  central obesity  |  18
C0038454  |  stroke  |  18
C0027051  |  myocardial infarction  |  17
C0020459  |  hyperinsulinemia  |  17
C0020473  |  hyperlipidemia  |  13
C0020456  |  hyperglycemia  |  12
C0018801  |  heart failure  |  12
C0242350  |  erectile dysfunction  |  11
C0376358  |  prostate cancer  |  10
C0271650  |  glucose intolerance  |  10
C0042373  |  vascular diseases  |  9
C0242339  |  dyslipidaemia  |  9
C0155626  |  acute myocardial infarction  |  9
C0007222  |  cardiovascular diseases  |  8
C0577631  |  carotid atherosclerosis  |  7
C0020443  |  hypercholesterolemia  |  6
C0948008  |  ischemic stroke  |  6
C2318511  |  nonalcoholic steatohepatitis  |  6
C0271790  |  subclinical hypothyroidism  |  5
C0242339  |  dyslipidemias  |  5
C0010068  |  coronary disease  |  5
C0022658  |  nephropathy  |  5
C0025517  |  metabolic disorder  |  4
C0149931  |  migraine  |  4
C0242231  |  coronary stenosis  |  3
C0035435  |  rheumatic diseases  |  2
C0033687  |  proteinuria  |  2
C0018802  |  congestive heart failure  |  2
C2711227  |  liver steatosis  |  2
C2675519  |  hypoadiponectinemia  |  2
C1863767  |  m syndrome  |  1
C0003972  |  atherosclerotic cardiovascular disease  |  1
C0022661  |  chronic renal failure  |  1
C0025517  |  metabolic disorders  |  1
Manually Genotype(Total Text Mining Genotypes:0)
(Waiting for update.)
Text Mining Genotype(Total Genotypes:0)
(Waiting for update.)
All Snps(Total Genotypes:465)
snpId pubmedId geneId geneSymbol diseaseId sourceId sentence score Year geneSymbol_dbSNP CHROMOSOME POS REF ALT
rs10010131188531346934TCF7L2umls:C0524620BeFreePolymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004).0.1290011892008WFS146291188AG
rs10096633250236344023LPLumls:C0524620BeFreeA novel African American-specific variant, rs12721054/APOC1, and rs10096633/LPL are associated with ≥3 MetS components.0.1396310292015NA819973410CT
rs10227520694148746TMEM258umls:C0524620GWASCATA genome-wide association study of the metabolic syndrome in Indian Asian men.0.122010TMEM2581161790331TC
rs10282458223838923123HLA-DRB1umls:C0524620BeFreeCorresponding eSNPs were tested for association with MetS-related phenotypes in two GWAS of >100,000 individuals; rs10282458, affecting expression of RARRES2 (encoding chemerin), was associated with body mass index (BMI) (P = 6.0×10(-4)); and rs2395185, affecting inter-depot differences of HLA-DRB1 expression, was associated with high-density lipoprotein (P = 8.7×10(-4)) and BMI-adjusted waist-to-hip ratio (P = 2.4×10(-4)).0.0008143262012NA7150348213GA
rs10282458223838925919RARRES2umls:C0524620BeFreeCorresponding eSNPs were tested for association with MetS-related phenotypes in two GWAS of >100,000 individuals; rs10282458, affecting expression of RARRES2 (encoding chemerin), was associated with body mass index (BMI) (P = 6.0×10(-4)); and rs2395185, affecting inter-depot differences of HLA-DRB1 expression, was associated with high-density lipoprotein (P = 8.7×10(-4)) and BMI-adjusted waist-to-hip ratio (P = 2.4×10(-4)).0.0021715352012NA7150348213GA
rs1028583216337283172HNF4Aumls:C0524620BeFreeNine SNPs spanning the HNF4 alpha P2 promoter (rs4810424, rs1884613 and rs1884614) and coding region (rs2144908, rs6031551, rs6031552, rs1885088, rs1028583 and rs3818247) were genotyped in 160 subjects without diabetes or metabolic syndrome.0.0013572092011HNF4A2044422121TG
rs1040288214719724306NR3C2umls:C0524620BeFreeIn the MS population, the C/G and G/G genotypes of single-nucleotide polymorphism rs1040288 (NR3C2) and A/G and G/G of rs11099680 (NR3C2) were associated with uncontrolled AHT (odds ratio (OR)=2.94 (1.34-6.47) and OR=2.54 (1.09-5.93), respectively).0.0013572092011NR3C24148126966GC
rs1041981201776547124TNFumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0220740062010LTA;LOC100287329631573007CA
rs1041981201776544049LTAumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0087297472010LTA;LOC100287329631573007CA
rs1041981157295814049LTAumls:C0524620BeFreeThe common T60N polymorphism of the lymphotoxin-alpha gene is associated with type 2 diabetes and other phenotypes of the metabolic syndrome.0.0087297472005LTA;LOC100287329631573007CA
rs104271122900502154ADRB2umls:C0524620BeFreeADRB2 haplotypes (comprising rs1042711, rs1801704, rs1042713 and rs1042714 in that order), genotyping and statistical analysis to evaluate associations with continuous variables and traits related to IR and MS in a PCOS population.0.0134638112013ADRB25148826785CA,T
rs104271322900502154ADRB2umls:C0524620BeFreeADRB2 haplotypes (comprising rs1042711, rs1801704, rs1042713 and rs1042714 in that order), genotyping and statistical analysis to evaluate associations with continuous variables and traits related to IR and MS in a PCOS population.0.0134638112013ADRB25148826877GA
rs104271422900502154ADRB2umls:C0524620BeFreeADRB2 haplotypes (comprising rs1042711, rs1801704, rs1042713 and rs1042714 in that order), genotyping and statistical analysis to evaluate associations with continuous variables and traits related to IR and MS in a PCOS population.0.0134638112013ADRB25148826910GC,T
rs10447248217008799370ADIPOQumls:C0524620BeFreeIn addition, we found that FER SNP rs10447248 was related to HDL cholesterol levels (P = 0.009); ADIPOQ variation was associated with fasting glucose (P = 0.04), HDL cholesterol (P = 0.04), and a metabolic syndrome score (P = 0.002).0.1848946042011NA5108580035AG
rs10447248217008792241FERumls:C0524620BeFreeIn addition, we found that FER SNP rs10447248 was related to HDL cholesterol levels (P = 0.009); ADIPOQ variation was associated with fasting glucose (P = 0.04), HDL cholesterol (P = 0.04), and a metabolic syndrome score (P = 0.002).0.0002714422011NA5108580035AG
rs1046801721386085102724766LOC102724766umls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.122011LOC1027247661558386313CT
rs107901622138608584811BUD13umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1226384742011BUD1311116768388AG,T
rs107901622138608584811BUD13umls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1226384742011BUD1311116768388AG,T
rs108386812239952710062NR1H3umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1250055062012NR1H31147253513GA
rs108386812239952710062NR1H3umls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1250055062012NR1H31147253513GA
rs108503352217036184811BUD13umls:C0524620BeFreeDietary calcium intake appears to be inversely associated with the risk of metabolic syndrome and may modulate susceptibility to the syndrome in subjects who are minor allele carriers of rs6445834 in ARHGEF3, rs10850335 in TBX5, or rs180349 in BUD13.0.1226384742012TBX512114375303TC
rs1093839721147891132789GNPDA2umls:C0524620BeFreeGNPDA2 rs10938397 was also significantly associated with MetS (P(age, sex-adjusted)=0.011, OR (95% CI): 1.20 (1.04, 1.38)) in the case-control study.0.0005428842011NA445180510AG
rs1093839724269186132789GNPDA2umls:C0524620BeFreeOf 11 SNPs, GNPDA2 rs10938397, BDNF rs6265, and FAIM2 rs7138803 were nominally associated with risk of MetS (GNPDA2 rs10938397: odds ratio (OR)=1.21, 95% confidence interval (CI)=1.04-1.40, P=0.016; BDNF rs6265: OR=1.19, 95% CI=1.03-1.39, P=0.021; FAIM2 rs7138803: OR=1.20, 95% CI=1.02-1.40, P=0.025); genetic risk score (GRS) was significantly associated with risk of MetS (OR=1.09, 95% CI=1.04-1.15, P=5.26×10(-4)).0.0005428842013NA445180510AG
rs1106628025705158283450HECTD4umls:C0524620GWASCATPathway Analysis of Metabolic Syndrome Using a Genome-Wide Association Study of Korea Associated Resource (KARE) Cohorts.0.122014HECTD412112379979TA
rs11099680214719724306NR3C2umls:C0524620BeFreeIn the MS population, the C/G and G/G genotypes of single-nucleotide polymorphism rs1040288 (NR3C2) and A/G and G/G of rs11099680 (NR3C2) were associated with uncontrolled AHT (odds ratio (OR)=2.94 (1.34-6.47) and OR=2.54 (1.09-5.93), respectively).0.0013572092011NR3C24148182095GA
rs112706522399527816CAMK2Bumls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1223670322012CAMK2B744220272CT,G
rs112706522399527816CAMK2Bumls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1223670322012CAMK2B744220272CT,G
rs113360716521160123876ACSM2Aumls:C0524620BeFreeThe L513S polymorphism in medium-chain acyl-CoA synthetase 2 (MACS2) is associated with risk factors of the metabolic syndrome in a Caucasian study population.0.0002714422006ACSM2A1620483086CG,T
rs1133607165211604082MARCKSumls:C0524620BeFreeAssociation studies in the Japanese Suita cohort of MACS polymorphisms and various phenotypes revealed the contribution of the Leu513Ser polymorphism in MACS2 to multiple risk factors of the metabolic syndrome.0.0002714422006ACSM2A1620483086CG,T
rs11336071652116054453RIN2umls:C0524620BeFreeAssociation studies in the Japanese Suita cohort of MACS polymorphisms and various phenotypes revealed the contribution of the Leu513Ser polymorphism in MACS2 to multiple risk factors of the metabolic syndrome.0.0002714422006ACSM2A1620483086CG,T
rs113360716521160116285ACSM1umls:C0524620BeFreeThe L513S polymorphism in medium-chain acyl-CoA synthetase 2 (MACS2) is associated with risk factors of the metabolic syndrome in a Caucasian study population.0.0002714422006ACSM2A1620483086CG,T
rs1137101193442163953LEPRumls:C0524620BeFreeAssociation between the Gln223Arg polymorphism of the leptin receptor and metabolic syndrome in free-living community elderly.0.0124539892009LEPR165592830AG
rs1137101227344603952LEPumls:C0524620BeFreeRelationship between leptin G2548A and leptin receptor Q223R gene polymorphisms and obesity and metabolic syndrome risk in Tunisian volunteers.0.2169489482012LEPR165592830AG
rs1137101227344603953LEPRumls:C0524620BeFreeRelationship between leptin G2548A and leptin receptor Q223R gene polymorphisms and obesity and metabolic syndrome risk in Tunisian volunteers.0.0124539892012LEPR165592830AG
rs11545881183283511149CIDEAumls:C0524620BeFreeCell death-inducing DNA fragmentation factor alpha-like effector A (CIDEA) gene V115F (G-->T) polymorphism is associated with phenotypes of metabolic syndrome in Japanese men.0.0031813582008CIDEA1812274105GA,C,T
rs11545881211062681149CIDEAumls:C0524620BeFreeAssociation of the cell death-inducing DNA fragmentation factor alpha-like effector A (CIDEA) gene V115F (G/T) polymorphism with phenotypes of metabolic syndrome in a Chinese population.0.0031813582011CIDEA1812274105GA,C,T
rs11724758239113002169FABP2umls:C0524620BeFreeCorrelations between FABP2 rs11724758 polymorphisms and components of MetS reveal that high-density lipoprotein cholesterol (HDL-c) levels are significantly higher in FABP2 rs11724758 AA genotype carrier compared with noncarriers, whereas triglycerides (TG) and fasting plasma glucose (FG) were to be significantly lower in the AA genotype carrier.0.0171880522013FABP24119318723GA
rs1175543253667595468PPARGumls:C0524620BeFreeAnalysis of the haplotype and linkage disequilibrium of PPARγ gene polymorphisms rs3856806, rs12490265, rs1797912, and rs1175543 among patients with metabolic syndrome in Kazakh of Xinjiang Province.0.1450042242015PPARG312424934AG
rs11774572193646393630INSumls:C0524620BeFreePolymorphism rs11774572 was significantly associated with MetS (P=0.020), mainly driven by the association of the C allele with lower HDL-C (P=0.043) and higher triglycerides (P=0.049) and insulin (P=0.040) concentrations than TT subjects.0.1669594442010NA811589291CT
rs118205892138608584811BUD13umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1226384742011BUD1311116763146GA
rs118205892138608584811BUD13umls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1226384742011BUD1311116763146GA
rs11823543213860858882ZPR1umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1252769482011ZPR111116778419GA
rs118251812138608584811BUD13umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1226384742011BUD1311116755542GA
rs11868035239858081401CRPumls:C0524620BeFreeWe followed up 212 randomly selected, nonobese, nondiabetic, insulin-sensitive participants in a population-based study without NAFLD or metabolic syndrome at baseline who were characterized for the common SREBF-1c gene rs11868035 A/G polymorphism, dietary habits, physical activity, adipokine profile, C-reactive protein (CRP), and circulating markers of endothelial dysfunction.0.136958882013SREBF1;RAI11717811787GA
rs118875341517535264240ABCG5umls:C3714619BeFreeLow serum cholesterol and cholesterol absorption were linked to the D19H polymorphism of the ABCG8 gene, and characteristics of the insulin resistance syndrome in men were linked with the Q604E polymorphism of the ABCG5 gene.0.0002714422004ABCG5;ABCG8243839108GA,C
rs118875341517535264241ABCG8umls:C3714619BeFreeLow serum cholesterol and cholesterol absorption were linked to the D19H polymorphism of the ABCG8 gene, and characteristics of the insulin resistance syndrome in men were linked with the Q604E polymorphism of the ABCG5 gene.0.0002714422004ABCG5;ABCG8243839108GA,C
rs118875341517535264240ABCG5umls:C0524620BeFreeLow serum cholesterol and cholesterol absorption were linked to the D19H polymorphism of the ABCG8 gene, and characteristics of the insulin resistance syndrome in men were linked with the Q604E polymorphism of the ABCG5 gene.0.0002714422004ABCG5;ABCG8243839108GA,C
rs118875341517535264241ABCG8umls:C0524620BeFreeLow serum cholesterol and cholesterol absorption were linked to the D19H polymorphism of the ABCG8 gene, and characteristics of the insulin resistance syndrome in men were linked with the Q604E polymorphism of the ABCG5 gene.0.0029099162004ABCG5;ABCG8243839108GA,C
rs12051272258758113630INSumls:C0524620BeFreeAfter further adjustment for the adiponectin levels, participants with a minor allele of rs12051272 revealed a considerable association with a more favorable metabolic profile, including higher insulin sensitivity, high-density lipoprotein cholesterol levels, lower diastolic blood pressure, circulating levels of fasting plasma glucose, and triglycerides, and as a lower risk of metabolic syndrome (all P < 0.05).0.1669594442015CDH131682629683GT
rs12086634238694183290HSD11B1umls:C0524620BeFreeWe conclude that in a South Indian population, a polymorphism of the HSD11B1 gene containing the single-nucleotide polymorphism (SNP) rs12086634 T→G confers increased risk of metabolic syndrome.0.0861672182014HSD11B1;LOC1019301141209706914TG
rs12286037213860858882ZPR1umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1252769482011ZPR111116781491CT
rs12286037213860858882ZPR1umls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1252769482011ZPR111116781491CT
rs12490265253667595468PPARGumls:C0524620BeFreeAnalysis of the haplotype and linkage disequilibrium of PPARγ gene polymorphisms rs3856806, rs12490265, rs1797912, and rs1175543 among patients with metabolic syndrome in Kazakh of Xinjiang Province.0.1450042242015PPARG312343043GA
rs12503643201768584149MAXumls:C0524620BeFreeWe investigated the relationship between ACSL1 polymorphisms (rs4862417, rs6552828, rs13120078, rs9997745, and rs12503643) and MetS risk and determined potential interactions with dietary fat in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1,754).0.0013572092010ACSL1;LOC1053775874184824934GT
rs1260326188531342646GCKRumls:C0524620BeFreeA polymorphism in the GCKR gene predicted dyslipidaemia (rs1260326, OR 1.15, 95% CI 1.09-1.22, p < 0.00001) but not the metabolic syndrome.0.1287297472008GCKR227508073TC
rs12691222699632805GOT1umls:C0524620BeFreeA gene variation (rs12691) in the CCAT/enhancer binding protein α modulates glucose metabolism in metabolic syndrome.0.0005428842011CEBPA1933300221GA
rs12721054250236344023LPLumls:C0524620BeFreeA novel African American-specific variant, rs12721054/APOC1, and rs10096633/LPL are associated with ≥3 MetS components.0.1396310292015APOC11944919330AG
rs130228732138608584450ZNF512umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.0023670322011ZNF512227592643AC
rs13120078201768584149MAXumls:C0524620BeFreeWe investigated the relationship between ACSL1 polymorphisms (rs4862417, rs6552828, rs13120078, rs9997745, and rs12503643) and MetS risk and determined potential interactions with dietary fat in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1,754).0.0013572092010ACSL14184810288GA
rs132266502239952751085MLXIPLumls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1226384742012MLXIPL773602675AG
rs132266502239952751085MLXIPLumls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1226384742012MLXIPL773602675AG
rs132834561797909780142PTGES2umls:C0524620BeFreeProstaglandin E synthase 2 (PTGES2) Arg298His polymorphism and parameters of the metabolic syndrome.0.0026384742007PTGES29128122474CA,T
rs133291232749011401CRPumls:C0524620BeFreeIn a population-based study, we followed 175 nonobese, nondiabetic participants without NAFLD or metabolic syndrome at baseline, characterized for the SREBF-2 rs133291 C/T polymorphism, dietary habits, physical activity, adipokines, C-reactive protein (CRP), and endothelial adhesion molecules.0.136958882013SREBF22241873624CT
rs134316522062216857818G6PC2umls:C0524620GAD[Genetic and in situ functional data support a potential role for rs13431652, but not rs573225, as a causative SNP linking G6PC2 to variations in FPG, though a causative role for rs573225 in vivo cannot be ruled out.]0.1247340642010NA2168896905TC
rs141176625646961116519APOA5umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.1712927162014LOC105370358;LOC10537035913109599813GA
rs1411766256469614036LRP2umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014LOC105370358;LOC10537035913109599813GA
rs1411766256469617350UCP1umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0039956832014LOC105370358;LOC10537035913109599813GA
rs14117662564696123158TBC1D9umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014LOC105370358;LOC10537035913109599813GA
rs14117662564696123026MYO16umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014LOC105370358;LOC10537035913109599813GA
rs1411766256469618660IRS2umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0039956832014LOC105370358;LOC10537035913109599813GA
rs14230962412370256729RETNumls:C0524620BeFreeHowever, rs1423096, downstream of RETN, seems to be associated with MetS and T2DM risk more so than rs3745367.0.1309012822013NA197674291TC
rs1441756213860854023LPLumls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1396310292011NA820010875AC
rs146052672235121623630INSumls:C0524620BeFreeAssociation between rs146052672 variant and MetS occurred independently of T2D, indicating that HMGA1 gene defects play a pathogenetic role in MetS and other insulin-resistance-related conditions.0.1669594442013NANANANANA
rs1479355258673983482IGF2Rumls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0002714422016IGF2R6160109594TC
rs1479355258673986616SNAP25umls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0026384742016IGF2R6160109594TC
rs1479355258673986833ABCC8umls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0026384742016IGF2R6160109594TC
rs15285213860854023LPLumls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1396310292011LPL819967156CT
rs153208522399527102724766LOC102724766umls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.122012LOC1027247661558391167AG
rs1535206941489415FADS2umls:C0524620GWASCATA genome-wide association study of the metabolic syndrome in Indian Asian men.0.1226384742010FADS21161830500AG
rs1570070258673986833ABCC8umls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0026384742016IGF2R6160032946AG
rs1570070258673983482IGF2Rumls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0002714422016IGF2R6160032946AG
rs1570070258673986616SNAP25umls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0026384742016IGF2R6160032946AG
rs1575822239952710452TOMM40umls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1223670322012TOMM401944892962CT
rs1575822239952710452TOMM40umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1223670322012TOMM401944892962CT
rs16147248972394852NPYumls:C0524620BeFreeAssociation of neuropeptide Y gene rs16147 polymorphism with metabolic syndrome in patients with documented coronary artery disease.0.0039956832015NPY724283791TC
rs16874954250780677941PLA2G7umls:C0524620BeFreeCarriage of the V279F homozygous genotype, a rare allele, within the gene encoding Lp-PLA2 leads to changes in circulating intermediate metabolites in individuals without metabolic syndrome.0.0805428842015NANANANANA
rs17173608229820165919RARRES2umls:C0524620BeFreeAssociation between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report.0.0021715352012RARRES27150339575TG
rs173539213860859709HERPUD1umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.0047340642011NA1656954132CT
rs174546206941483992FADS1umls:C0524620GWASCATA genome-wide association study of the metabolic syndrome in Indian Asian men.0.122010FADS11161802358CT
rs1760272918855224270AMPD1umls:C0524620GAD[Association of C34T AMPD1 gene polymorphism with features of metabolic syndrome in patients with coronary artery disease or heart failure.]0.0026384742009AMPD11114693436GA
rs17611196197031493CTLA4umls:C0524620BeFreeIn a marker-by-marker analysis, the ADRB2 rs180088 (OR 1.22, 95% CI 1.01-1.48) and PAI1 rs1799768 (OR 1.05, 95% CI 1.01-1.10) were associated with an increased MetS risk, whereas the C5 rs17611 (OR 0.95, 95% CI 0.91-1.00) and the CTLA4 rs5742909 (OR 0.91, 95% CI 0.84-0.99) were associated with a decreased risk.0.0002714422009C59121006922CT
rs176166722588808948CD36umls:C0524620BeFreeOur findings show that CD36 rs1761667 SNP is positively associated with increased risk of MetS and its components with genotype AG heterozygotes showing highest frequency among MetS patients.0.0893485762012CD36780615623GA
rs17782312231014784160MC4Rumls:C0524620BeFreeIn this study we found support for the hypothesis that weight regulation and insulin metabolism are involved in MetS development.MC4R rs17782312 and IRS1 rs2943634 may explain part of the genetic variation in MetS.0.0063627152012NANANANANA
rs17782312231014783667IRS1umls:C0524620BeFreeIn this study we found support for the hypothesis that weight regulation and insulin metabolism are involved in MetS development.MC4R rs17782312 and IRS1 rs2943634 may explain part of the genetic variation in MetS.0.0871770412012NANANANANA
rs1797912253667595468PPARGumls:C0524620BeFreeAnalysis of the haplotype and linkage disequilibrium of PPARγ gene polymorphisms rs3856806, rs12490265, rs1797912, and rs1175543 among patients with metabolic syndrome in Kazakh of Xinjiang Province.0.1450042242015PPARG312428740AC
rs1799768196197031493CTLA4umls:C0524620BeFreeIn a marker-by-marker analysis, the ADRB2 rs180088 (OR 1.22, 95% CI 1.01-1.48) and PAI1 rs1799768 (OR 1.05, 95% CI 1.01-1.10) were associated with an increased MetS risk, whereas the C5 rs17611 (OR 0.95, 95% CI 0.91-1.00) and the CTLA4 rs5742909 (OR 0.91, 95% CI 0.84-0.99) were associated with a decreased risk.0.0002714422009SERPINE17101126425-G
rs1799768196197035054SERPINE1umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.016330122009SERPINE17101126425-G
rs179976819619703185AGTR1umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.014821022009SERPINE17101126425-G
rs179976819619703154ADRB2umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.0134638112009SERPINE17101126425-G
rs1799768196197033552IL1Aumls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.0031813582009SERPINE17101126425-G
rs1799821228095521376CPT2umls:C0524620BeFreeWe performed an analysis including three coding SNP in the muscle isoform of the CPT1b gene (rs3213445, rs2269383 and rs470117) and one coding SNP in the CPT2 gene (rs1799821) to find associations with traits of the metabolic syndrome (MetS).0.0005428842013CPT2153210776GA
rs179988315869758345APOC3umls:C0524620BeFreeAGT T174M, GNB3 825C>T, and APOC3 -455T>C genotypes were significantly associated with MetS (P = 0.018, 0.0056, and 0.029, respectively) for female adults, whereas FABP2 A54T genotype was associated with MetS (P = 0.040) for female adolescents.0.1007267282006FABP24119320747TG,C,A
rs1799883155472954547MTTPumls:C3714619BeFreeOur objectives were to determine whether Ala54Thr FABP2 and G-493T MTP polymorphisms are associated with increased risks of insulin resistance syndrome (IRS) in youth and/or modify the expression of accompanying dyslipidemia.0.0005428842005FABP24119320747TG,C,A
rs1799883155472954547MTTPumls:C0524620BeFreeOur objectives were to determine whether Ala54Thr FABP2 and G-493T MTP polymorphisms are associated with increased risks of insulin resistance syndrome (IRS) in youth and/or modify the expression of accompanying dyslipidemia.0.0048100092005FABP24119320747TG,C,A
rs1799883158697582169FABP2umls:C0524620BeFreeAGT T174M, GNB3 825C>T, and APOC3 -455T>C genotypes were significantly associated with MetS (P = 0.018, 0.0056, and 0.029, respectively) for female adults, whereas FABP2 A54T genotype was associated with MetS (P = 0.040) for female adolescents.0.0171880522006FABP24119320747TG,C,A
rs179988315869758183AGTumls:C0524620BeFreeAGT T174M, GNB3 825C>T, and APOC3 -455T>C genotypes were significantly associated with MetS (P = 0.018, 0.0056, and 0.029, respectively) for female adults, whereas FABP2 A54T genotype was associated with MetS (P = 0.040) for female adolescents.0.0890011892006FABP24119320747TG,C,A
rs1799883169195422169FABP2umls:C0524620BeFreeThr54 allele carriers of the Ala54Thr variant of FABP2 gene have associations with metabolic syndrome and hypertriglyceridemia in urban South Indians.0.0171880522006FABP24119320747TG,C,A
rs1799883158697582784GNB3umls:C0524620BeFreeAGT T174M, GNB3 825C>T, and APOC3 -455T>C genotypes were significantly associated with MetS (P = 0.018, 0.0056, and 0.029, respectively) for female adults, whereas FABP2 A54T genotype was associated with MetS (P = 0.040) for female adolescents.0.0090011892006FABP24119320747TG,C,A
rs1799941256474066462SHBGumls:C0524620BeFreeSHBG gene polymorphism (rs1799941) associates with metabolic syndrome in children and adolescents.0.1232573022014SHBG177630105GA
rs1799983223045424846NOS3umls:C0524620BeFreeThe eNOS 894T allele carriers are at greater risk for both MtS and ED, suggesting that eNOS G894T gene polymorphism might play an implication as a common genetic susceptibility factor to develop both disorders.0.143822212012NOS37150999023TG
rs179998320163778627BDNFumls:C0524620BeFreeWe found that genotype Met/Met of the Val66Met polymorphism of the brain-derived neurotrophic factor gene was positively associated with depressive disorder (P < 0.05), but we were not able to find any significant associations of both the depressive disorder and metabolic syndrome with the remaining polymorphisms studied (methylenetetrahydrofolate reductase 677CT, methylenetet rahydrofolate reductase 1298AC, endothelial nitric oxide synthase Glu298Asp, and tyrosine hydroxylase).0.0031813582010NOS37150999023TG
rs1799983201637787054THumls:C0524620BeFreeWe found that genotype Met/Met of the Val66Met polymorphism of the brain-derived neurotrophic factor gene was positively associated with depressive disorder (P < 0.05), but we were not able to find any significant associations of both the depressive disorder and metabolic syndrome with the remaining polymorphisms studied (methylenetetrahydrofolate reductase 677CT, methylenetet rahydrofolate reductase 1298AC, endothelial nitric oxide synthase Glu298Asp, and tyrosine hydroxylase).0.0026384742010NOS37150999023TG
rs1799983186403914846NOS3umls:C0524620BeFreeThe association of endothelial nitric oxide synthase G894T polymorphism with C-reactive protein level and metabolic syndrome in a Chinese study group.0.143822212008NOS37150999023TG
rs1799983186403911401CRPumls:C0524620BeFreeThe association of endothelial nitric oxide synthase G894T polymorphism with C-reactive protein level and metabolic syndrome in a Chinese study group.0.136958882008NOS37150999023TG
rs1799983218167834846NOS3umls:C0524620BeFreeNOS3 Glu298Asp polymorphism interacts with virgin olive oil phenols to determine the postprandial endothelial function in patients with the metabolic syndrome.0.143822212011NOS37150999023TG
rs1799983201637784524MTHFRumls:C0524620BeFreeWe found that genotype Met/Met of the Val66Met polymorphism of the brain-derived neurotrophic factor gene was positively associated with depressive disorder (P < 0.05), but we were not able to find any significant associations of both the depressive disorder and metabolic syndrome with the remaining polymorphisms studied (methylenetetrahydrofolate reductase 677CT, methylenetet rahydrofolate reductase 1298AC, endothelial nitric oxide synthase Glu298Asp, and tyrosine hydroxylase).0.0156353462010NOS37150999023TG
rs1799998172614711585CYP11B2umls:C0524620BeFree-344C/T Variant in the promoter of the aldosterone synthase gene (CYP11B2) is associated with metabolic syndrome in men.0.0029099162007CYP11B2;LOC1053757938142918184AG
rs18002062187795654512EXOSC4umls:C0524620BeFreeThe frequency distribution of rare alleles for PPARα (L162V) and PPARγ (P12A and H449H) was compared using the chi square test in 363 HIV-1-infected patients classified according to the presence or absence of the metabolic syndrome after 48 months of follow-up on their first PI-containing regimen.0.0010857672012PPARA2246218377CG
rs1800206153096805465PPARAumls:C0524620BeFreeAssociation between the PPARalpha-L162V polymorphism and components of the metabolic syndrome.0.0071770412004PPARA2246218377CG
rs1800206266739685467PPARDumls:C0524620BeFreeThis study aimed to investigate the association of peroxisome proliferator-activated receptor (PPAR) genes PPARα L162V, PPARγ2 C161T and PPARδ T294C single nucleotide polymorphisms (SNPs) with obesity and metabolic syndrome (Met-S) in a multi-ethnic population in Kampar, Malaysia.0.0063627152016PPARA2246218377CG
rs180058719619703185AGTR1umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.014821022009IL1A2112785383GC,A
rs180058719619703154ADRB2umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.0134638112009IL1A2112785383GC,A
rs1800587196197035054SERPINE1umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.016330122009IL1A2112785383GC,A
rs1800587196197033552IL1Aumls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.0031813582009IL1A2112785383GC,A
rs180059225646961116519APOA5umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.1712927162014NA4140572807TC
rs180059224138564155ADRB3umls:C0524620BeFreeWe investigated whether the -3826A/G polymorphism (rs1800592) of the uncoupling protein 1 gene (UCP1) and the Trp64Arg polymorphism (rs4994) of the β3-adrenergic receptor gene (ADRB3) are associated with type 2 diabetes mellitus (T2DM) and features of metabolic syndrome in a Brazilian-Caucasian population.0.0288277152014NA4140572807TC
rs1800592256469614036LRP2umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014NA4140572807TC
rs18005922564696123158TBC1D9umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014NA4140572807TC
rs1800592256469617350UCP1umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0039956832014NA4140572807TC
rs1800592256469618660IRS2umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0039956832014NA4140572807TC
rs18005922564696123026MYO16umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014NA4140572807TC
rs1800592241385647350UCP1umls:C0524620BeFreeWe investigated whether the -3826A/G polymorphism (rs1800592) of the uncoupling protein 1 gene (UCP1) and the Trp64Arg polymorphism (rs4994) of the β3-adrenergic receptor gene (ADRB3) are associated with type 2 diabetes mellitus (T2DM) and features of metabolic syndrome in a Brazilian-Caucasian population.0.0039956832014NA4140572807TC
rs1800610201776547124TNFumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0220740062010TNF631576050GA
rs1800610201776544049LTAumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0087297472010TNF631576050GA
rs1800629201776544049LTAumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0087297472010TNF631575254GA
rs1800629201776547124TNFumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0220740062010TNF631575254GA
rs1800630201776547124TNFumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0220740062010LTA;TNF631574699CA
rs1800630201776544049LTAumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0087297472010LTA;TNF631574699CA
rs18007972008084128411IGHV3-71umls:C0524620BeFreePossession of the IL-6 rs1800797 GG genotype by the LTA and TNF-alpha risk genotype carriers further increased risk of the MetS [OR 2.10 (CI 1.19-3.71) P = 0.009], fasting hyperglycemia [OR 2.65 (CI 1.12-6.28), P = 0.027], high systolic blood pressure [OR 1.99 (CI 1.07-3.72), P = 0.03], and abdominal obesity [OR 1.52 (CI 1.01-2.28), P = 0.04].0.0002714422010IL6;LOC541472722726602AG
rs180088196197033552IL1Aumls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.0031813582009NA1769951455TC
rs18008819619703185AGTR1umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.014821022009NA1769951455TC
rs18008819619703154ADRB2umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.0134638112009NA1769951455TC
rs180088196197031493CTLA4umls:C0524620BeFreeIn a marker-by-marker analysis, the ADRB2 rs180088 (OR 1.22, 95% CI 1.01-1.48) and PAI1 rs1799768 (OR 1.05, 95% CI 1.01-1.10) were associated with an increased MetS risk, whereas the C5 rs17611 (OR 0.95, 95% CI 0.91-1.00) and the CTLA4 rs5742909 (OR 0.91, 95% CI 0.84-0.99) were associated with a decreased risk.0.0002714422009NA1769951455TC
rs180088196197035054SERPINE1umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.016330122009NA1769951455TC
rs1801132220116272100ESR2umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0034527992012ESR16151944387GC
rs1801132220116272099ESR1umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0069055992012ESR16151944387GC
rs180125324972470155ADRB3umls:C0524620BeFreeThe objective of this work was to analyze the association of polymorphisms in ADRB1 (rs1801253) (Arg389Gly) and ADRB3 (Trp64Arg) genes with T2D and metabolic syndrome (MS).0.0288277152015ADRB110114045297GC
rs180125324972470153ADRB1umls:C0524620BeFreeThe objective of this work was to analyze the association of polymorphisms in ADRB1 (rs1801253) (Arg389Gly) and ADRB3 (Trp64Arg) genes with T2D and metabolic syndrome (MS).0.0002714422015ADRB110114045297GC
rs1801260243287279575CLOCKumls:C0524620BeFreeBeneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome.0.0124539892014CLOCK;TMEM165455435202AG
rs1801260243287273630INSumls:C0524620BeFreeBeneficial effect of CLOCK gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome.0.1669594442014CLOCK;TMEM165455435202AG
rs1801276187163983667IRS1umls:C0524620BeFreeThe polymorphisms PstI and MaeIII of INS, NsiI of INSR and Ala513Pro and Gly972Arg of IRS1 have been associated with metabolic syndrome; moreover, the products of these genes are functionally contiguous during insulin signaling.0.0871770412009IRS12226797205CG
rs1801276187163983630INSumls:C0524620BeFreeThe polymorphisms PstI and MaeIII of INS, NsiI of INSR and Ala513Pro and Gly972Arg of IRS1 have been associated with metabolic syndrome; moreover, the products of these genes are functionally contiguous during insulin signaling.0.1669594442009IRS12226797205CG
rs1801276187163983643INSRumls:C0524620BeFreeThe polymorphisms PstI and MaeIII of INS, NsiI of INSR and Ala513Pro and Gly972Arg of IRS1 have been associated with metabolic syndrome; moreover, the products of these genes are functionally contiguous during insulin signaling.0.0008143262009IRS12226797205CG
rs1801278187163983630INSumls:C0524620BeFreeThe polymorphisms PstI and MaeIII of INS, NsiI of INSR and Ala513Pro and Gly972Arg of IRS1 have been associated with metabolic syndrome; moreover, the products of these genes are functionally contiguous during insulin signaling.0.1669594442009IRS12226795828CT,G,A
rs1801278187163983643INSRumls:C0524620BeFreeThe polymorphisms PstI and MaeIII of INS, NsiI of INSR and Ala513Pro and Gly972Arg of IRS1 have been associated with metabolic syndrome; moreover, the products of these genes are functionally contiguous during insulin signaling.0.0008143262009IRS12226795828CT,G,A
rs1801278201703522784GNB3umls:C0524620BeFreeTo assess the prevalence of IRS-1 Gly972Arg and GNB3 C825T polymorphisms in women with polycystic ovary syndrome (PCOS) and their relation to the metabolic syndrome and hyperandrogenaemia.0.0090011892010IRS12226795828CT,G,A
rs1801278201703523667IRS1umls:C0524620BeFreeTo assess the prevalence of IRS-1 Gly972Arg and GNB3 C825T polymorphisms in women with polycystic ovary syndrome (PCOS) and their relation to the metabolic syndrome and hyperandrogenaemia.0.0871770412010IRS12226795828CT,G,A
rs1801278187163983667IRS1umls:C0524620BeFreeThe polymorphisms PstI and MaeIII of INS, NsiI of INSR and Ala513Pro and Gly972Arg of IRS1 have been associated with metabolic syndrome; moreover, the products of these genes are functionally contiguous during insulin signaling.0.0871770412009IRS12226795828CT,G,A
rs1801278216459403667IRS1umls:C0524620BeFreeThe rs1801278 G>A polymorphism of IRS-1 is associated with metabolic syndrome in healthy nondiabetic men. Modulation by cigarette smoking status.0.0871770412011IRS12226795828CT,G,A
rs1801282126309565468PPARGumls:C0524620BeFreeThese results suggest that the PPAR-gamma P12A polymorphism can modulate the association between dietary fat intake and components of the metabolic syndrome.0.1450042242003PPARG312351626CG
rs1801282218779565468PPARGumls:C0524620BeFreeThere was no convincing association between any polymorphism of PPARα and PPARγ and each individual component of the metabolic syndrome, except for the relationship of the P12A polymorphism with diabetes.0.1450042242012PPARG312351626CG
rs1801282242430835468PPARGumls:C0524620BeFreeWe investigated the synergism between variants at the PPARγ locus (C161T and Pro12Ala polymorphisms) with insulin resistance on metabolic syndrome (MS).0.1450042242013PPARG312351626CG
rs1801282221682105468PPARGumls:C0524620BeFreePPARγ Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome.0.1450042242011PPARG312351626CG
rs1801282197455525468PPARGumls:C0524620BeFreeHealthy men, in particular nonsmokers, carrying the Ala12 allele of PPARG rs1801282 polymorphism, have a high risk for MetS and IR.0.1450042242009PPARG312351626CG
rs1801282121615485468PPARGumls:C3714619BeFreeComment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome.0.0008143262002PPARG312351626CG
rs180128216916989348APOEumls:C0524620BeFreeThe Pro12Ala PPARG sequence variant together with a non-E3/E3 APOE genotype is associated with a high risk for postprandial hypertriglyceridemia in patients with the metabolic syndrome, indicating a close association between these genes and the regulation of lipoproteinase clearance.0.0320090732006PPARG312351626CG
rs18012822187795654512EXOSC4umls:C0524620BeFreeThe frequency distribution of rare alleles for PPARα (L162V) and PPARγ (P12A and H449H) was compared using the chi square test in 363 HIV-1-infected patients classified according to the presence or absence of the metabolic syndrome after 48 months of follow-up on their first PI-containing regimen.0.0010857672012PPARG312351626CG
rs1801282221682101636ACEumls:C0524620BeFreePPARγ Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome.0.0371004552011PPARG312351626CG
rs1801282218779565465PPARAumls:C0524620BeFreeThere was no convincing association between any polymorphism of PPARα and PPARγ and each individual component of the metabolic syndrome, except for the relationship of the P12A polymorphism with diabetes.0.0071770412012PPARG312351626CG
rs1801282244641855468PPARGumls:C0524620BeFreeAssociations between C1431T and Pro12Ala variants of PPARγ gene and their haplotypes with susceptibility to metabolic syndrome in an Iranian population.0.1450042242014PPARG312351626CG
rs1801282196098445468PPARGumls:C0524620BeFreeThe Pro12Ala PPARgamma polymorphism does not seem to be associated with BMI or metabolic syndrome parameters in postmenopausal Polish women, although the X/Ala genotype seems to predispose to a less favorable lipid profile in this population.0.1450042242009PPARG312351626CG
rs1801282121615485468PPARGumls:C0524620BeFreeComment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome.0.1450042242002PPARG312351626CG
rs1801282169169895468PPARGumls:C0524620BeFreePro12Ala sequence variant of the PPARG gene is associated with postprandial hypertriglyceridemia in non-E3/E3 patients with the metabolic syndrome.0.1450042242006PPARG312351626CG
rs1801282183624245468PPARGumls:C0524620BeFreeThe frequencies of 2 common polymorphisms of the PPARgamma gene, Pro12Ala single nucleotide polymorphism (SNP) in exon B and C161T SNP in exon 6, were investigated in 792 subjects and the correlations between the different genotypes, IR and metabolic syndrome (MS) were analyzed.0.1450042242008PPARG312351626CG
rs1801282162169165225PGCumls:C0524620BeFreeOur objective was to search for differences in genotypes of peroxisome proliferator-activated receptor gamma (PPARgamma) (Pro12 Ala) and its coactivator PGC-1alpha (Gly482 Ser) in adolescents harboring features of metabolic syndrome.0.0005428842005PPARG312351626CG
rs1801282242000524023LPLumls:C0524620BeFreeIn the group of participants with PPARγ Pro12Ala or Ala12Ala genotypes, those with the LPL Pvu (-/+) or (+/+) genotype had greater odds for MetSy (odds ratio OR=5.98; 95% confidence interval CI: 1.46-24.47, p=0.013).0.1396310292014PPARG312351626CG
rs1801394254294304552MTRRumls:C0524620BeFreeAssociations of MTHFR C677T and MTRR A66G gene polymorphisms with metabolic syndrome: a case-control study in Northern China.0.0002714422014MTRR;FASTKD357870860AG
rs1801394254294304524MTHFRumls:C0524620BeFreeAssociations of MTHFR C677T and MTRR A66G gene polymorphisms with metabolic syndrome: a case-control study in Northern China.0.0156353462014MTRR;FASTKD357870860AG
rs180170422900502154ADRB2umls:C0524620BeFreeADRB2 haplotypes (comprising rs1042711, rs1801704, rs1042713 and rs1042714 in that order), genotyping and statistical analysis to evaluate associations with continuous variables and traits related to IR and MS in a PCOS population.0.0134638112013ADRB25148826812CT
rs1803492217036184811BUD13umls:C0524620BeFreeDietary calcium intake appears to be inversely associated with the risk of metabolic syndrome and may modulate susceptibility to the syndrome in subjects who are minor allele carriers of rs6445834 in ARHGEF3, rs10850335 in TBX5, or rs180349 in BUD13.0.1226384742012NA11116741111AT
rs1805094217447413953LEPRumls:C0524620BeFreeLys656Asn polymorphism of leptin receptor gene and metabolic syndrome in obese patients.0.0124539892011LEPR165610269GC
rs1805192221682105468PPARGumls:C0524620BeFreePPARγ Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome.0.1450042242011PPARG312379739CG
rs1805192121615485468PPARGumls:C3714619BeFreeComment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome.0.0008143262002PPARG312379739CG
rs1805192242000524023LPLumls:C0524620BeFreeIn the group of participants with PPARγ Pro12Ala or Ala12Ala genotypes, those with the LPL Pvu (-/+) or (+/+) genotype had greater odds for MetSy (odds ratio OR=5.98; 95% confidence interval CI: 1.46-24.47, p=0.013).0.1396310292014PPARG312379739CG
rs18051922187795654512EXOSC4umls:C0524620BeFreeThe frequency distribution of rare alleles for PPARα (L162V) and PPARγ (P12A and H449H) was compared using the chi square test in 363 HIV-1-infected patients classified according to the presence or absence of the metabolic syndrome after 48 months of follow-up on their first PI-containing regimen.0.0010857672012PPARG312379739CG
rs1805192126309565468PPARGumls:C0524620BeFreeThese results suggest that the PPAR-gamma P12A polymorphism can modulate the association between dietary fat intake and components of the metabolic syndrome.0.1450042242003PPARG312379739CG
rs1805192244641855468PPARGumls:C0524620BeFreeAssociations between C1431T and Pro12Ala variants of PPARγ gene and their haplotypes with susceptibility to metabolic syndrome in an Iranian population.0.1450042242014PPARG312379739CG
rs1805192218779565468PPARGumls:C0524620BeFreeThere was no convincing association between any polymorphism of PPARα and PPARγ and each individual component of the metabolic syndrome, except for the relationship of the P12A polymorphism with diabetes.0.1450042242012PPARG312379739CG
rs1805192183624245468PPARGumls:C0524620BeFreeThe frequencies of 2 common polymorphisms of the PPARgamma gene, Pro12Ala single nucleotide polymorphism (SNP) in exon B and C161T SNP in exon 6, were investigated in 792 subjects and the correlations between the different genotypes, IR and metabolic syndrome (MS) were analyzed.0.1450042242008PPARG312379739CG
rs1805192169169895468PPARGumls:C0524620BeFreePro12Ala sequence variant of the PPARG gene is associated with postprandial hypertriglyceridemia in non-E3/E3 patients with the metabolic syndrome.0.1450042242006PPARG312379739CG
rs1805192218779565465PPARAumls:C0524620BeFreeThere was no convincing association between any polymorphism of PPARα and PPARγ and each individual component of the metabolic syndrome, except for the relationship of the P12A polymorphism with diabetes.0.0071770412012PPARG312379739CG
rs1805192162169165225PGCumls:C0524620BeFreeOur objective was to search for differences in genotypes of peroxisome proliferator-activated receptor gamma (PPARgamma) (Pro12 Ala) and its coactivator PGC-1alpha (Gly482 Ser) in adolescents harboring features of metabolic syndrome.0.0005428842005PPARG312379739CG
rs1805192221682101636ACEumls:C0524620BeFreePPARγ Pro12Ala and ACE ID polymorphisms are associated with BMI and fat distribution, but not metabolic syndrome.0.0371004552011PPARG312379739CG
rs1805192121615485468PPARGumls:C0524620BeFreeComment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome.0.1450042242002PPARG312379739CG
rs1805192196098445468PPARGumls:C0524620BeFreeThe Pro12Ala PPARgamma polymorphism does not seem to be associated with BMI or metabolic syndrome parameters in postmenopausal Polish women, although the X/Ala genotype seems to predispose to a less favorable lipid profile in this population.0.1450042242009PPARG312379739CG
rs180519216916989348APOEumls:C0524620BeFreeThe Pro12Ala PPARG sequence variant together with a non-E3/E3 APOE genotype is associated with a high risk for postprandial hypertriglyceridemia in patients with the metabolic syndrome, indicating a close association between these genes and the regulation of lipoproteinase clearance.0.0320090732006PPARG312379739CG
rs1805192242430835468PPARGumls:C0524620BeFreeWe investigated the synergism between variants at the PPARγ locus (C161T and Pro12Ala polymorphisms) with insulin resistance on metabolic syndrome (MS).0.1450042242013PPARG312379739CG
rs185847354150634299370ADIPOQumls:C0524620BeFreeThe I164T mutation in the adiponectin gene was a common genetic background associated with the metabolic syndrome and CAD in the Japanese population.0.1848946042004ADIPOQ;ADIPOQ-AS13186854460TC
rs18830252239952719ABCA1umls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1258198312012ABCA19104902020CT
rs18830252239952719ABCA1umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1258198312012ABCA19104902020CT
rs1884613216337283172HNF4Aumls:C0524620BeFreeNine SNPs spanning the HNF4 alpha P2 promoter (rs4810424, rs1884613 and rs1884614) and coding region (rs2144908, rs6031551, rs6031552, rs1885088, rs1028583 and rs3818247) were genotyped in 160 subjects without diabetes or metabolic syndrome.0.0013572092011LOC1053726292044351775CG
rs1884614216337283172HNF4Aumls:C0524620BeFreeNine SNPs spanning the HNF4 alpha P2 promoter (rs4810424, rs1884613 and rs1884614) and coding region (rs2144908, rs6031551, rs6031552, rs1885088, rs1028583 and rs3818247) were genotyped in 160 subjects without diabetes or metabolic syndrome.0.0013572092011LOC1053726292044351879CT
rs1885088216337283172HNF4Aumls:C0524620BeFreeNine SNPs spanning the HNF4 alpha P2 promoter (rs4810424, rs1884613 and rs1884614) and coding region (rs2144908, rs6031551, rs6031552, rs1885088, rs1028583 and rs3818247) were genotyped in 160 subjects without diabetes or metabolic syndrome.0.0013572092011HNF4A2044410400GA
rs19191282138608584226C2orf16umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.0023670322011C2orf16227578892AG
rs2000813193801369388LIPGumls:C0524620BeFreeWe examined associations between variants LIPG T111I (rs2000813) and LIPG i24582 (rs6507931), HDL and television viewing/computer use (screen time) as a marker for physical inactivity in a population with high prevalence of metabolic syndrome.0.0010857672009LIPG1849567494CT
rs204308521386085102724766LOC102724766umls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.122011LOC1027247661558388755TC
rs2075263208555664149MAXumls:C0524620BeFreeThis study determined the relationship between ACC2 polymorphisms (rs2075263, rs2268387, rs2284685, rs2284689, rs2300453, rs3742023, rs3742026, rs4766587, and rs6606697) and MetS risk, and whether dietary fatty acids modulate this in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754).0.0013572092010ACACB12109266520CT
rs2075290213860858882ZPR1umls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1252769482011ZPR111116782580CT
rs2075290213860858882ZPR1umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1252769482011ZPR111116782580CT
rs2108622224840218529CYP4F2umls:C0524620BeFreeThe functional variant V433M of the CYP4F2 and the metabolic syndrome in Swedes.0.0002714422012CYP4F21915879621CT
rs2144908216337283172HNF4Aumls:C0524620BeFreeNine SNPs spanning the HNF4 alpha P2 promoter (rs4810424, rs1884613 and rs1884614) and coding region (rs2144908, rs6031551, rs6031552, rs1885088, rs1028583 and rs3818247) were genotyped in 160 subjects without diabetes or metabolic syndrome.0.0013572092011HNF4A;LOC1053726292044357077GA
rs2197089213860854023LPLumls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1396310292011NA819968862GA
rs2206277213860857021TFAP2Bumls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1223670322011TFAP2B650830813CT
rs2206277213860857021TFAP2Bumls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1223670322011TFAP2B650830813CT
rs2228145234791533570IL6Rumls:C0524620BeFreeInfluence of the 48867A>C (Asp358Ala) IL6R polymorphism on response to a lifestyle modification intervention in individuals with metabolic syndrome.0.0010857672014IL6R1154454494AC,T
rs2229094201776544049LTAumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0087297472010LTA;LOC100287329631572779TC
rs2229094201776547124TNFumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0220740062010LTA;LOC100287329631572779TC
rs2229616182396464160MC4Rumls:C0524620BeFreeAssociation of the MC4R V103I polymorphism with the metabolic syndrome: the KORA Study.0.0063627152008MC4R1860372043CT
rs2234693220116272099ESR1umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0069055992012ESR16151842200TC
rs2234693220116272100ESR2umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0034527992012ESR16151842200TC
rs2236242229820165919RARRES2umls:C0524620BeFreeAssociation between chemerin rs17173608 and vaspin rs2236242 gene polymorphisms and the metabolic syndrome, a preliminary report.0.0021715352012SERPINA121494493715TA
rs2241766235906059370ADIPOQumls:C0524620BeFreeAim of the study was to evaluate the prevalence of metabolic symptoms in patients with PA compared to controls and the prevalence of two single nucleotide polymorphisms (SNPs), T45G and G276T, in the adiponectin gene and their relationship to metabolic syndrome (MS).0.1848946042014ADIPOQ;ADIPOQ-AS13186853103TG
rs2241883174852342168FABP1umls:C0524620BeFreeTo determine the possible role of the common FABP1 T94A polymorphism in modulating susceptibility to traits of the metabolic syndrome, we analysed a random sample of 826 subjects from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam cohort.0.0026384742007FABP1288124547TC
rs2250141819829454512EXOSC4umls:C0524620BeFreeInteraction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome.0.0010857672007DIO21480203237TC
rs225014181982941734DIO2umls:C0524620BeFreeInteraction of DIO2 T92A and PPARgamma2 P12A polymorphisms in the modulation of metabolic syndrome.0.0026384742007DIO21480203237TC
rs2266788213860858882ZPR1umls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1252769482011ZPR1;APOA511116789970GA
rs226678821386085116519APOA5umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1712927162011ZPR1;APOA511116789970GA
rs226678821386085116519APOA5umls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1712927162011ZPR1;APOA511116789970GA
rs2266788213860858882ZPR1umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1252769482011ZPR1;APOA511116789970GA
rs2268387208555664149MAXumls:C0524620BeFreeThis study determined the relationship between ACC2 polymorphisms (rs2075263, rs2268387, rs2284685, rs2284689, rs2300453, rs3742023, rs3742026, rs4766587, and rs6606697) and MetS risk, and whether dietary fatty acids modulate this in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754).0.0013572092010ACACB12109205890AG
rs2269383228095521376CPT2umls:C0524620BeFreeWe performed an analysis including three coding SNP in the muscle isoform of the CPT1b gene (rs3213445, rs2269383 and rs470117) and one coding SNP in the CPT2 gene (rs1799821) to find associations with traits of the metabolic syndrome (MetS).0.0005428842013CPT1B;CHKB-CPT1B2250574346CT
rs2284685208555664149MAXumls:C0524620BeFreeThis study determined the relationship between ACC2 polymorphisms (rs2075263, rs2268387, rs2284685, rs2284689, rs2300453, rs3742023, rs3742026, rs4766587, and rs6606697) and MetS risk, and whether dietary fatty acids modulate this in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754).0.0013572092010ACACB12109248977GC
rs2284689208555664149MAXumls:C0524620BeFreeThis study determined the relationship between ACC2 polymorphisms (rs2075263, rs2268387, rs2284685, rs2284689, rs2300453, rs3742023, rs3742026, rs4766587, and rs6606697) and MetS risk, and whether dietary fatty acids modulate this in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754).0.0013572092010ACACB12109247740AG
rs22954901938981857761TRIB3umls:C0524620BeFreeTRIB3 functional Q84R polymorphism is a risk factor for metabolic syndrome and carotid atherosclerosis.0.1226384742009TRIB320388261AG
rs2300453208555664149MAXumls:C0524620BeFreeThis study determined the relationship between ACC2 polymorphisms (rs2075263, rs2268387, rs2284685, rs2284689, rs2300453, rs3742023, rs3742026, rs4766587, and rs6606697) and MetS risk, and whether dietary fatty acids modulate this in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754).0.0013572092010ACACB12109217349TG
rs2395185223838925919RARRES2umls:C0524620BeFreeCorresponding eSNPs were tested for association with MetS-related phenotypes in two GWAS of >100,000 individuals; rs10282458, affecting expression of RARRES2 (encoding chemerin), was associated with body mass index (BMI) (P = 6.0×10(-4)); and rs2395185, affecting inter-depot differences of HLA-DRB1 expression, was associated with high-density lipoprotein (P = 8.7×10(-4)) and BMI-adjusted waist-to-hip ratio (P = 2.4×10(-4)).0.0021715352012NA632465390GT
rs2395185223838923123HLA-DRB1umls:C0524620BeFreeCorresponding eSNPs were tested for association with MetS-related phenotypes in two GWAS of >100,000 individuals; rs10282458, affecting expression of RARRES2 (encoding chemerin), was associated with body mass index (BMI) (P = 6.0×10(-4)); and rs2395185, affecting inter-depot differences of HLA-DRB1 expression, was associated with high-density lipoprotein (P = 8.7×10(-4)) and BMI-adjusted waist-to-hip ratio (P = 2.4×10(-4)).0.0008143262012NA632465390GT
rs247617223995279709HERPUD1umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.0047340642012NA1656956804CA
rs25262462192006528965SLC27A6umls:C0524620BeFreeA total of 755 male participants from a Metabolic Intervention Cohort Kiel were genotyped for the FATP6-7T>A polymorphism (rs2526246) and phenotyped for features of the metabolic syndrome.0.0005428842012SLC27A65128966131TA
rs254439025646961116519APOA5umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.1712927162014LRP22169348336CT
rs2544390256469617350UCP1umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0039956832014LRP22169348336CT
rs2544390256469618660IRS2umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0039956832014LRP22169348336CT
rs25443902564696123026MYO16umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014LRP22169348336CT
rs2544390256469614036LRP2umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014LRP22169348336CT
rs25443902564696123158TBC1D9umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014LRP22169348336CT
rs266729238457803630INSumls:C0524620BeFreeNo association was detected between SNP rs266729 and other clusters of metabolic syndrome or their traits except for HOMA-IR and fasting plasma insulin levels, p-values 0.035 and 0.004, respectively.0.1669594442013ADIPOQ3186841685CG
rs268223995274023LPLumls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1396310292012LPL819956018AG
rs268223995274023LPLumls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1396310292012LPL819956018AG
rs2813544220116272100ESR2umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0034527992012NA6152104447AG
rs2813544220116272099ESR1umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0069055992012NA6152104447AG
rs291016425958310406938MIR146Aumls:C0524620BeFreeAssociation of MicroRNA-146a rs2910164 Gene Polymorphism with Metabolic Syndrome.0.0002714422016LOC285628;MIR146A5160485411CG
rs291841918194492595CCND1umls:C0524620BeFreeOur objective was to test the association of rs2918419, a T-->C single nucleotide change in intron 2 downstream of the Bcl1 locus, with components of the metabolic syndrome and its interaction with the Bcl1 locus.0.0002714422008NR3C15143342788TC
rs2943634231014783667IRS1umls:C0524620BeFreeIn this study we found support for the hypothesis that weight regulation and insulin metabolism are involved in MetS development.MC4R rs17782312 and IRS1 rs2943634 may explain part of the genetic variation in MetS.0.0871770412012NA2226203364AC,G
rs2943634231014784160MC4Rumls:C0524620BeFreeIn this study we found support for the hypothesis that weight regulation and insulin metabolism are involved in MetS development.MC4R rs17782312 and IRS1 rs2943634 may explain part of the genetic variation in MetS.0.0063627152012NA2226203364AC,G
rs295213860854023LPLumls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1396310292011LPL819958727AC
rs295213860854023LPLumls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1396310292011LPL819958727AC
rs29540332138608510221TRIB1umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.0026384742011LOC1053757458125481504AG
rs301213860854023LPLumls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1396310292011LPL819959423TC
rs301213860854023LPLumls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1396310292011LPL819959423TC
rs3017887258889351535CYBAumls:C0524620BeFreeThe results suggest that the evaluated NOX4 and CYBA SNPs are not direct genetic determinants of fibrosis in HCV patients, but nevertheless NOX4 rs3017887 SNP could indirectly influence fibrosis susceptibility due to its inverse association with MS in male patients.0.0802714422015NOX41189492920AC
rs3020450220116272100ESR2umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0034527992012ESR21464301584CT,A
rs3020450220116272099ESR1umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0069055992012ESR21464301584CT,A
rs309984422399527352961HCG26umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.0023670322012LOC102725068631481199CA
rs3135506217496083569IL6umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1437125892011APOA511116791691GA,C
rs313550621749608345APOC3umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1007267282011APOA511116791691GA,C
rs3135506217496086934TCF7L2umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1290011892011APOA511116791691GA,C
rs313550621749608116519APOA5umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1712927162011APOA511116791691GA,C
rs3213445228095521376CPT2umls:C0524620BeFreeWe performed an analysis including three coding SNP in the muscle isoform of the CPT1b gene (rs3213445, rs2269383 and rs470117) and one coding SNP in the CPT2 gene (rs1799821) to find associations with traits of the metabolic syndrome (MetS).0.0005428842013CPT1B;CHKB-CPT1B2250577409TC
rs361525201776547124TNFumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0220740062010TNF631575324GA
rs361525201776544049LTAumls:C0524620BeFreeSix common genetic variants (rs2229094, rs1041981, rs1800630, rs1800629, rs361525, and rs1800610) in the TNF-LTA locus encoding the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF-alpha) and lymphotoxin-alpha have been shown to be associated with various metabolic traits including susceptibility to type 2 diabetes, metabolic syndrome, insulin resistance, and increased body mass index (BMI) in Caucasians from different geographic locations and have yielded mixed results.0.0087297472010TNF631575324GA
rs362551258673986616SNAP25umls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0026384742016NA2010314788CA
rs362551258673986833ABCC8umls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0026384742016NA2010314788CA
rs362551258673983482IGF2Rumls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0002714422016NA2010314788CA
rs369953112217496086934TCF7L2umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1290011892011IL6722731416TC
rs36995311221749608116519APOA5umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1712927162011IL6722731416TC
rs369953112217496083569IL6umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1437125892011IL6722731416TC
rs36995311221749608345APOC3umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1007267282011IL6722731416TC
rs37325811875882655486PARLumls:C0524620GAD[Association of PARL rs3732581 genetic variant with insulin levels, metabolic syndrome and coronary artery disease.]0.0023670322008PARL3183840614CT,G
rs3732581187588263630INSumls:C0524620BeFreeNo significant associations were observed between rs3732581 and levels of plasma insulin, glucose, BMI or MetS in either population.0.1669594442008PARL3183840614CT,G
rs3742023208555664149MAXumls:C0524620BeFreeThis study determined the relationship between ACC2 polymorphisms (rs2075263, rs2268387, rs2284685, rs2284689, rs2300453, rs3742023, rs3742026, rs4766587, and rs6606697) and MetS risk, and whether dietary fatty acids modulate this in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754).0.0013572092010ACACB12109256177CT
rs3742026208555664149MAXumls:C0524620BeFreeThis study determined the relationship between ACC2 polymorphisms (rs2075263, rs2268387, rs2284685, rs2284689, rs2300453, rs3742023, rs3742026, rs4766587, and rs6606697) and MetS risk, and whether dietary fatty acids modulate this in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754).0.0013572092010ACACB12109232852GT,C
rs37453672412370256729RETNumls:C0524620BeFreeHowever, rs1423096, downstream of RETN, seems to be associated with MetS and T2DM risk more so than rs3745367.0.1309012822013RETN197669625GA
rs37491472138608579635CCDC121umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.0023670322011GPN1;CCDC121227629051GA
rs37491472138608511321GPN1umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.0023670322011GPN1;CCDC121227629051GA
rs3757840223995272645GCKumls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.0058198312012NA744191617TG
rs3758391205032583087HHEXumls:C0524620BeFreeNominally significant associations were also observed between T2D and the SIRT1 rs3758391 SNP and MS and the HHEX rs5015480 polymorphism.0.0002714422010SIRT11067883584TC
rs37583912050325823411SIRT1umls:C0524620BeFreeNominally significant associations were also observed between T2D and the SIRT1 rs3758391 SNP and MS and the HHEX rs5015480 polymorphism.0.2042671252010SIRT11067883584TC
rs37594585521749608345APOC3umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1007267282011TCF7L210113165792CT
rs375945855217496083569IL6umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1437125892011TCF7L210113165792CT
rs37594585521749608116519APOA5umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1712927162011TCF7L210113165792CT
rs375945855217496086934TCF7L2umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1290011892011TCF7L210113165792CT
rs3764261213860859709HERPUD1umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.0047340642011NA1656959412CA
rs37904332003247754741LEPROTumls:C0524620BeFreeLEPR rs3790433 GG homozygotes had increased MetS risk compared with the minor A allele carriers [odds ratio (OR) = 1.65; 95% CI: 1.05-2.57; P = 0.028], which may be accounted for by their increased risk of elevated insulin concentrations (OR 2.40; 95% CI: 1.28-4.50; P = 0.006) and insulin resistance (OR = 2.15; 95% CI: 1.18-3.90; P = 0.012).0.0013572092010LEPR;LEPROT165428659CT
rs3813929185158913358HTR2Cumls:C0524620BeFreePatients (n=134) were assessed for measures of obesity, other factors contributing to metabolic syndrome, and two genetic polymorphisms (5-HT(2C) receptor -759C/T and leptin -2548A/G).0.1263627152008HTR2CX114584047CT
rs3816873167214864547MTTPumls:C0524620BeFreeEmerging evidence has indicated that the functional MTP exon polymorphism I128T is associated with dyslipidemia and other traits of the insulin-resistance syndrome, and the T128 variant seems to confer a reduced stability of MTP, resulting in reduced binding of LDL particles.0.0048100092006MTTP499583507TC
rs3816873167214864547MTTPumls:C3714619BeFreeEmerging evidence has indicated that the functional MTP exon polymorphism I128T is associated with dyslipidemia and other traits of the insulin-resistance syndrome, and the T128 variant seems to confer a reduced stability of MTP, resulting in reduced binding of LDL particles.0.0005428842006MTTP499583507TC
rs3818247216337283172HNF4Aumls:C0524620BeFreeNine SNPs spanning the HNF4 alpha P2 promoter (rs4810424, rs1884613 and rs1884614) and coding region (rs2144908, rs6031551, rs6031552, rs1885088, rs1028583 and rs3818247) were genotyped in 160 subjects without diabetes or metabolic syndrome.0.0013572092011HNF4A2044428840GT
rs3818569258673986616SNAP25umls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0026384742016NANANANANA
rs3818569258673986833ABCC8umls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0026384742016NANANANANA
rs3818569258673983482IGF2Rumls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0002714422016NANANANANA
rs3856806258964115468PPARGumls:C0524620BeFreeThe C1431T polymorphism of peroxisome proliferator activated receptor-γ (PPAR-γ) gene is related to diabetes and metabolic-syndrome.0.1450042242015PPARG312434058CT
rs3856806253667595468PPARGumls:C0524620BeFreeAnalysis of the haplotype and linkage disequilibrium of PPARγ gene polymorphisms rs3856806, rs12490265, rs1797912, and rs1175543 among patients with metabolic syndrome in Kazakh of Xinjiang Province.0.1450042242015PPARG312434058CT
rs3856806244641855468PPARGumls:C0524620BeFreeAssociations between C1431T and Pro12Ala variants of PPARγ gene and their haplotypes with susceptibility to metabolic syndrome in an Iranian population.0.1450042242014PPARG312434058CT
rs3856806216437575468PPARGumls:C0524620BeFreeThe C1431T polymorphism in peroxisome proliferator-activated receptor-γ (PPARγ) has been shown to be associated with diabetes, obesity, and metabolic syndrome.0.1450042242012PPARG312434058CT
rs3856806211568355468PPARGumls:C0524620BeFreeWe concluded that the CC genotype of C1431T in the PPARγ2 gene together with low cardiorespiratory fitness may increase the risk of MetS in younger men (age < 40 yr), even with adjustment for age.0.1450042242011PPARG312434058CT
rs386513644208512971268CNR1umls:C0524620BeFreeG1359A polymorphism in the cannabinoid receptor-1 gene is associated with metabolic syndrome in the Chinese Han population.0.0039956832010NANANANANA
rs386513644214728411268CNR1umls:C0524620BeFreeRelation of G1359A polymorphism of the cannabinoid receptor (CB1) gene with metabolic syndrome by ATP III classification.0.0039956832011NANANANANA
rs3865278351797909780142PTGES2umls:C0524620BeFreeProstaglandin E synthase 2 (PTGES2) Arg298His polymorphism and parameters of the metabolic syndrome.0.0026384742007NANANANANA
rs386539811223085354852NPYumls:C0524620BeFreeNeuropeptide Y Leu7Pro polymorphism associated with the metabolic syndrome and its features in patients with coronary artery disease.0.0039956832013NANANANANA
rs386602118201637787054THumls:C0524620BeFreeWe found that genotype Met/Met of the Val66Met polymorphism of the brain-derived neurotrophic factor gene was positively associated with depressive disorder (P < 0.05), but we were not able to find any significant associations of both the depressive disorder and metabolic syndrome with the remaining polymorphisms studied (methylenetetrahydrofolate reductase 677CT, methylenetet rahydrofolate reductase 1298AC, endothelial nitric oxide synthase Glu298Asp, and tyrosine hydroxylase).0.0026384742010NANANANANA
rs386602118201637784524MTHFRumls:C0524620BeFreeWe found that genotype Met/Met of the Val66Met polymorphism of the brain-derived neurotrophic factor gene was positively associated with depressive disorder (P < 0.05), but we were not able to find any significant associations of both the depressive disorder and metabolic syndrome with the remaining polymorphisms studied (methylenetetrahydrofolate reductase 677CT, methylenetet rahydrofolate reductase 1298AC, endothelial nitric oxide synthase Glu298Asp, and tyrosine hydroxylase).0.0156353462010NANANANANA
rs38660211823967328627BDNFumls:C0524620BeFreeAssociation study of Val66Met polymorphism in brain-derived neurotrophic factor gene with clozapine-induced metabolic syndrome: preliminary results.0.0031813582013NANANANANA
rs38660211820163778627BDNFumls:C0524620BeFreeWe found that genotype Met/Met of the Val66Met polymorphism of the brain-derived neurotrophic factor gene was positively associated with depressive disorder (P < 0.05), but we were not able to find any significant associations of both the depressive disorder and metabolic syndrome with the remaining polymorphisms studied (methylenetetrahydrofolate reductase 677CT, methylenetet rahydrofolate reductase 1298AC, endothelial nitric oxide synthase Glu298Asp, and tyrosine hydroxylase).0.0031813582010NANANANANA
rs397507444223709934524MTHFRumls:C0524620BeFreeSubjects were screened for the metabolic syndrome (National Cholesterol Education Program Adult Treatment Panel III criteria) and MTHFR 677C/T, MTHFR 1298A/C, and Val158Met genotypes.0.0156353462012MTHFR111794407TG
rs397508822238105051080CFTRumls:C0524620BeFreeTen novel variants (c.2554_2555insT, p.F1107L, c.-152G>C, p.L323P, p.L32M, c.2883_2886dupGTCA, c.2349_2350insT, p.K114del, c.-602A>T, and c.2822delT) were associated with a CF phenotype (42% of participants were diagnosed at 4 to 25 months of age), whereas 26 were associated with CFTR-related metabolic syndrome to date.0.0013572092013CFTR7117540201CT
rs4343180575311636ACEumls:C0524620GAD[Homogeneous assay of rs4343, an ACE I/D proxy, and an analysis in the British Women's Heart and Health Study (BWHHS).]0.0371004552008ACE1763488670GA
rs4402960188531346934TCF7L2umls:C0524620BeFreePolymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004).0.1290011892008IGF2BP23185793899GT
rs4641173274604000LMNAumls:C0524620BeFreeLMNA maps to the well-replicated diabetes-linkage region on chromosome 1q, and there are reported associations between LMNA single nucleotide polymorphisms (SNPs) (particularly rs4641; H566H) and metabolic syndrome components.0.0050814512007LMNA1156137743CT
rs470117228095521376CPT2umls:C0524620BeFreeWe performed an analysis including three coding SNP in the muscle isoform of the CPT1b gene (rs3213445, rs2269383 and rs470117) and one coding SNP in the CPT2 gene (rs1799821) to find associations with traits of the metabolic syndrome (MetS).0.0005428842013CPT1B;CHKB-CPT1B2250571524CT
rs4766587208555664149MAXumls:C0524620BeFreeThis study determined the relationship between ACC2 polymorphisms (rs2075263, rs2268387, rs2284685, rs2284689, rs2300453, rs3742023, rs3742026, rs4766587, and rs6606697) and MetS risk, and whether dietary fatty acids modulate this in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754).0.0013572092010ACACB12109247525GA
rs47665872085556632ACACBumls:C0524620BeFreeIn conclusion, the ACC2 rs4766587 polymorphism influences MetS risk, which was modulated by dietary fat, suggesting novel gene-nutrient interactions.0.0052769482010ACACB12109247525GA
rs4810424216337283172HNF4Aumls:C0524620BeFreeNine SNPs spanning the HNF4 alpha P2 promoter (rs4810424, rs1884613 and rs1884614) and coding region (rs2144908, rs6031551, rs6031552, rs1885088, rs1028583 and rs3818247) were genotyped in 160 subjects without diabetes or metabolic syndrome.0.0013572092011R3HDML2044346383GC
rs4846922223995272590GALNT2umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1223670322012GALNT21230171436TC
rs4846922223995272590GALNT2umls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1223670322012GALNT21230171436TC
rs4862417201768584149MAXumls:C0524620BeFreeWe investigated the relationship between ACSL1 polymorphisms (rs4862417, rs6552828, rs13120078, rs9997745, and rs12503643) and MetS risk and determined potential interactions with dietary fat in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1,754).0.0013572092010ACSL14184769447AG
rs4986938220116272100ESR2umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0034527992012ESR21464233098CT
rs4986938220116272099ESR1umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0069055992012ESR21464233098CT
rs499421034552155ADRB3umls:C0524620BeFreeRelationship between Trp64Arg mutation in the β3-adrenergic receptor gene and metabolic syndrome: a seven-year follow-up study.0.0288277152010ADRB3837966280AG
rs49949250462155ADRB3umls:C0524620BeFreeThe Trp64Arg polymorphism of the beta 3-Adrenergic receptor gene. Lack of association with NIDDM and features of insulin resistance syndrome.0.0288277151997ADRB3837966280AG
rs499424972470155ADRB3umls:C0524620BeFreeThe objective of this work was to analyze the association of polymorphisms in ADRB1 (rs1801253) (Arg389Gly) and ADRB3 (Trp64Arg) genes with T2D and metabolic syndrome (MS).0.0288277152015ADRB3837966280AG
rs499424138564155ADRB3umls:C0524620BeFreeWe investigated whether the -3826A/G polymorphism (rs1800592) of the uncoupling protein 1 gene (UCP1) and the Trp64Arg polymorphism (rs4994) of the β3-adrenergic receptor gene (ADRB3) are associated with type 2 diabetes mellitus (T2DM) and features of metabolic syndrome in a Brazilian-Caucasian population.0.0288277152014ADRB3837966280AG
rs49948721782155ADRB3umls:C0524620BeFreeA possible pathogenic mutation in the beta 3-adrenergic-receptor gene (Trp64Arg) has been reported to be associated with an earlier age of onset of non-insulin-dependent diabetes mellitus (NIDDM) and clinical features of the insulin resistance syndrome in Pima Indian, Finnish and French subjects.0.0288277151996ADRB3837966280AG
rs49948923875155ADRB3umls:C0524620BeFreeWe recently identified a mutation in the human beta 3-adrenergic receptor (beta 3AR) gene (codon 64 TGGTrp -> CGGArg; TRP64ARG) that associates with features of the insulin resistance syndrome and an earlier onset of noninsulin-dependent diabetes mellitus (NIDDM).0.0288277151996ADRB3837966280AG
rs499420503258155ADRB3umls:C0524620BeFreeIn contrast, the non-synonymous ADRB3 rs4994 polymorphism is associated with T2D and MS.0.0288277152010ADRB3837966280AG
rs49948721782155ADRB3umls:C3714619BeFreeA possible pathogenic mutation in the beta 3-adrenergic-receptor gene (Trp64Arg) has been reported to be associated with an earlier age of onset of non-insulin-dependent diabetes mellitus (NIDDM) and clinical features of the insulin resistance syndrome in Pima Indian, Finnish and French subjects.0.0024429771996ADRB3837966280AG
rs49948923875155ADRB3umls:C3714619BeFreeWe recently identified a mutation in the human beta 3-adrenergic receptor (beta 3AR) gene (codon 64 TGGTrp -> CGGArg; TRP64ARG) that associates with features of the insulin resistance syndrome and an earlier onset of noninsulin-dependent diabetes mellitus (NIDDM).0.0024429771996ADRB3837966280AG
rs49949250462155ADRB3umls:C3714619BeFreeThe Trp64Arg polymorphism of the beta 3-Adrenergic receptor gene. Lack of association with NIDDM and features of insulin resistance syndrome.0.0024429771997ADRB3837966280AG
rs499410441039155ADRB3umls:C3714619BeFreeThe Trp64Arg beta3AR variant is associated in some, but not all, studies with an earlier onset of Type 2 diabetes mellitus and features of the insulin resistance syndrome.0.0024429771999ADRB3837966280AG
rs499412965109155ADRB3umls:C3714619BeFreeTo determine whether this SNP affects insulin resistance syndrome associated with type 2 diabetes, we examined its effects on susceptibility to obesity, hyperlipidemia and hypertension in type 2 diabetic subjects and on susceptibility to type 2 diabetes by interaction with other frequent genes involved in lipid metabolism, namely, beta3-adrenergic receptor (b3AR) Trp64Arg, phosphodiesterase 3B (PDE3B) c.1389G>A or lysosomal acid lipase (LAL) Thr-6Pro.0.0024429772003ADRB3837966280AG
rs499423282015155ADRB3umls:C0524620BeFreeTrp64Arg polymorphism of the ADRB3 gene may affect VF accumulation and be associated with MS, a cluster of conditions involving aggravated lipid metabolism and higher blood pressure, in Japanese children.0.0288277152012ADRB3837966280AG
rs499410441039155ADRB3umls:C0524620BeFreeThe Trp64Arg beta3AR variant is associated in some, but not all, studies with an earlier onset of Type 2 diabetes mellitus and features of the insulin resistance syndrome.0.0288277151999ADRB3837966280AG
rs499424972470153ADRB1umls:C0524620BeFreeThe objective of this work was to analyze the association of polymorphisms in ADRB1 (rs1801253) (Arg389Gly) and ADRB3 (Trp64Arg) genes with T2D and metabolic syndrome (MS).0.0002714422015ADRB3837966280AG
rs4994241385647350UCP1umls:C0524620BeFreeWe investigated whether the -3826A/G polymorphism (rs1800592) of the uncoupling protein 1 gene (UCP1) and the Trp64Arg polymorphism (rs4994) of the β3-adrenergic receptor gene (ADRB3) are associated with type 2 diabetes mellitus (T2DM) and features of metabolic syndrome in a Brazilian-Caucasian population.0.0039956832014ADRB3837966280AG
rs499412965109155ADRB3umls:C0524620BeFreeTo determine whether this SNP affects insulin resistance syndrome associated with type 2 diabetes, we examined its effects on susceptibility to obesity, hyperlipidemia and hypertension in type 2 diabetic subjects and on susceptibility to type 2 diabetes by interaction with other frequent genes involved in lipid metabolism, namely, beta3-adrenergic receptor (b3AR) Trp64Arg, phosphodiesterase 3B (PDE3B) c.1389G>A or lysosomal acid lipase (LAL) Thr-6Pro.0.0288277152003ADRB3837966280AG
rs5015480205032583087HHEXumls:C0524620BeFreeNominally significant associations were also observed between T2D and the SIRT1 rs3758391 SNP and MS and the HHEX rs5015480 polymorphism.0.0002714422010NA1092705802CT
rs50154802050325823411SIRT1umls:C0524620BeFreeNominally significant associations were also observed between T2D and the SIRT1 rs3758391 SNP and MS and the HHEX rs5015480 polymorphism.0.2042671252010NA1092705802CT
rs512535211228593630INSumls:C0524620BeFreeApoB rs512535 and ApoA1 rs670 major G allele homozygotes had increased MetS risk (OR 1.65 [CI 1.24, 2.20], P = 0.0006; OR 1.42 [CI 1.08, 1.87], P = 0.013), which may be, partly, explained by their increased abdominal obesity and impaired insulin sensitivity (P<0.05) but not dyslipidemia.0.1669594442011APOB221044910TC
rs518619619703154ADRB2umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.0134638112009AGTR13148742201AC
rs5186196197035054SERPINE1umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.016330122009AGTR13148742201AC
rs518617211857185AGTR1umls:C0524620BeFreeQuantitated transcript haplotypes (QTH) of AGTR1, reduced abundance of mRNA haplotypes containing 1166C (rs5186:A>C), and relevance to metabolic syndrome traits.0.014821022007AGTR13148742201AC
rs518619619703185AGTR1umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.014821022009AGTR13148742201AC
rs5186196197033552IL1Aumls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.0031813582009AGTR13148742201AC
rs5443150334622784GNB3umls:C0524620BeFreeThe C825T polymorphism in the gene coding for the beta3 subunit of G proteins (GNB3) has been shown to be associated with several phenotypes such as hypertension, obesity, and diabetes mellitus comprising the metabolic syndrome.0.0090011892004GNB3;CDCA3126845711CT
rs5443201703523667IRS1umls:C0524620BeFreeTo assess the prevalence of IRS-1 Gly972Arg and GNB3 C825T polymorphisms in women with polycystic ovary syndrome (PCOS) and their relation to the metabolic syndrome and hyperandrogenaemia.0.0871770412010GNB3;CDCA3126845711CT
rs5443219798842784GNB3umls:C0524620BeFreeClinically silent adrenal adenomas - their relation to the metabolic syndrome and to GNB3 C825T gene polymorphism.0.0090011892011GNB3;CDCA3126845711CT
rs5443201703522784GNB3umls:C0524620BeFreeTo assess the prevalence of IRS-1 Gly972Arg and GNB3 C825T polymorphisms in women with polycystic ovary syndrome (PCOS) and their relation to the metabolic syndrome and hyperandrogenaemia.0.0090011892010GNB3;CDCA3126845711CT
rs5608872239952757818G6PC2umls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1247340642012G6PC22168906638TC
rs5608872239952757818G6PC2umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1247340642012G6PC22168906638TC
rs569805213860858647ABCB11umls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1223670322011ABCB112168926370AT
rs569805213860858647ABCB11umls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1223670322011ABCB112168926370AT
rs5742909196197031493CTLA4umls:C0524620BeFreeIn a marker-by-marker analysis, the ADRB2 rs180088 (OR 1.22, 95% CI 1.01-1.48) and PAI1 rs1799768 (OR 1.05, 95% CI 1.01-1.10) were associated with an increased MetS risk, whereas the C5 rs17611 (OR 0.95, 95% CI 0.91-1.00) and the CTLA4 rs5742909 (OR 0.91, 95% CI 0.84-0.99) were associated with a decreased risk.0.0002714422009CTLA42203867624CT
rs574291219619703185AGTR1umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.014821022009SCNN1A126349184AG
rs574291219619703154ADRB2umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.0134638112009SCNN1A126349184AG
rs5742912196197035054SERPINE1umls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.016330122009SCNN1A126349184AG
rs5742912196197036337SCNN1Aumls:C0524620BeFreeEffect modification of the SCNN1A rs5742912 on the MetS by hormone therapy use warrants further investigation.0.0002714422009SCNN1A126349184AG
rs5742912196197033552IL1Aumls:C0524620BeFreeIn postmenopausal women, an increased MetS risk was found for the ADRB2 rs180088 (OR 1.28, 95% CI 0.99-1.65), PAI1 rs1799768 (OR 1.07, 95% CI 1.01-1.14), SCNN1A rs5742912 (OR 1.22, 95% CI 1.01-1.47), and IL1A rs1800587 (OR 1.07, 95% CI 1.01-1.15), whereas the AGTR1 rs5186 (OR 0.93, 95% CI 0.87-0.99) was associated with decreased risk.0.0031813582009SCNN1A126349184AG
rs59914820237465454000LMNAumls:C0524620BeFreeWe report on a 46-year-old female patient with a heterozygous p.R28W LMNA mutation, who presented with a novel clinical phenotype comprising severe limb-girdle muscular dystrophy, pronounced partial lipodystrophy, cardiac conduction defect, polycystic ovary disease and a metabolic syndrome with insulin-resistant diabetes mellitus and hypertriglyceridemia.0.0050814512013LMNA1156115000CG,T
rs6031551216337283172HNF4Aumls:C0524620BeFreeNine SNPs spanning the HNF4 alpha P2 promoter (rs4810424, rs1884613 and rs1884614) and coding region (rs2144908, rs6031551, rs6031552, rs1885088, rs1028583 and rs3818247) were genotyped in 160 subjects without diabetes or metabolic syndrome.0.0013572092011HNF4A2044361074TC
rs6031552216337283172HNF4Aumls:C0524620BeFreeNine SNPs spanning the HNF4 alpha P2 promoter (rs4810424, rs1884613 and rs1884614) and coding region (rs2144908, rs6031551, rs6031552, rs1885088, rs1028583 and rs3818247) were genotyped in 160 subjects without diabetes or metabolic syndrome.0.0013572092011HNF4A2044361154CA
rs6195228015632908NR3C1umls:C0524620BeFreePrevious studies of the N363S and BclI SNP in the GR gene have shown a metabolic syndrome phenotype in mostly non-African populations.0.0053528932012NANANANANA
rs6195159198392908NR3C1umls:C0524620BeFreeThe N363S polymorphism of the glucocorticoid receptor and metabolic syndrome factors in men.0.0053528932005NANANANANA
rs626524269186132789GNPDA2umls:C0524620BeFreeOf 11 SNPs, GNPDA2 rs10938397, BDNF rs6265, and FAIM2 rs7138803 were nominally associated with risk of MetS (GNPDA2 rs10938397: odds ratio (OR)=1.21, 95% confidence interval (CI)=1.04-1.40, P=0.016; BDNF rs6265: OR=1.19, 95% CI=1.03-1.39, P=0.021; FAIM2 rs7138803: OR=1.20, 95% CI=1.02-1.40, P=0.025); genetic risk score (GRS) was significantly associated with risk of MetS (OR=1.09, 95% CI=1.04-1.15, P=5.26×10(-4)).0.0005428842013BDNF;BDNF-AS1127658369CT
rs64458342217036184811BUD13umls:C0524620BeFreeDietary calcium intake appears to be inversely associated with the risk of metabolic syndrome and may modulate susceptibility to the syndrome in subjects who are minor allele carriers of rs6445834 in ARHGEF3, rs10850335 in TBX5, or rs180349 in BUD13.0.1226384742012ARHGEF3356881691TC
rs6507931193801369388LIPGumls:C0524620BeFreeWe examined associations between variants LIPG T111I (rs2000813) and LIPG i24582 (rs6507931), HDL and television viewing/computer use (screen time) as a marker for physical inactivity in a population with high prevalence of metabolic syndrome.0.0010857672009LIPG1849586638CT
rs6552828201768584149MAXumls:C0524620BeFreeWe investigated the relationship between ACSL1 polymorphisms (rs4862417, rs6552828, rs13120078, rs9997745, and rs12503643) and MetS risk and determined potential interactions with dietary fat in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1,754).0.0013572092010ACSL14184804262AG
rs6606697208555664149MAXumls:C0524620BeFreeThis study determined the relationship between ACC2 polymorphisms (rs2075263, rs2268387, rs2284685, rs2284689, rs2300453, rs3742023, rs3742026, rs4766587, and rs6606697) and MetS risk, and whether dietary fatty acids modulate this in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754).0.0013572092010ACACB12109173915AG
rs662255000075444PON1umls:C0524620BeFreeAccording to our results, PON1 Q192R polymorphism is a risk marker for insulin resistance, a pathological factor involved in the development of metabolic syndrome.0.1271770412014PON1795308134TC
rs662250371135444PON1umls:C0524620BeFreeParaoxonase (PON)1 Q192R functional genotypes and PON1 Q192R genotype by smoking interactions are risk factors for the metabolic syndrome, but not overweight or obesity.0.1271770412015PON1795308134TC
rs6627992564696123158TBC1D9umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014APOA511116792991GA
rs662799256469617350UCP1umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0039956832014APOA511116792991GA
rs66279923468858116519APOA5umls:C0524620BeFreeEffects of APOA5 -1131T>C (rs662799) on fasting plasma lipids and risk of metabolic syndrome: evidence from a case-control study in China and a meta-analysis.0.1712927162013APOA511116792991GA
rs66279924709297116519APOA5umls:C0524620BeFreeGenetic variants of apolipoprotein A5 T-1131C and apolipoprotein E common polymorphisms and their relationship to features of metabolic syndrome in adult dyslipidemic patients.0.1712927162014APOA511116792991GA
rs66279924709297348APOEumls:C0524620BeFreeGenetic variants of apolipoprotein A5 T-1131C and apolipoprotein E common polymorphisms and their relationship to features of metabolic syndrome in adult dyslipidemic patients.0.0320090732014APOA511116792991GA
rs66279919055447116519APOA5umls:C0524620BeFreeApolipoprotein A5 gene -1131T/C polymorphism is associated with the risk of metabolic syndrome in ethnic Chinese in Taiwan.0.1712927162008APOA511116792991GA
rs662799256469614036LRP2umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014APOA511116792991GA
rs66279925646961116519APOA5umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.1712927162014APOA511116792991GA
rs66279924161374116519APOA5umls:C0524620BeFreeApolipoprotein A5 T-1131C variant and risk for metabolic syndrome in obese adolescents.0.1712927162013APOA511116792991GA
rs6627992564696123026MYO16umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014APOA511116792991GA
rs66279917922054116519APOA5umls:C0524620BeFreeApolipoprotein A5 T-1131C variant confers risk for metabolic syndrome.0.1712927162007APOA511116792991GA
rs662799256469618660IRS2umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0039956832014APOA511116792991GA
rs670211228593630INSumls:C0524620BeFreeApoB rs512535 and ApoA1 rs670 major G allele homozygotes had increased MetS risk (OR 1.65 [CI 1.24, 2.20], P = 0.0006; OR 1.42 [CI 1.08, 1.87], P = 0.013), which may be, partly, explained by their increased abdominal obesity and impaired insulin sensitivity (P<0.05) but not dyslipidemia.0.1669594442011APOA1;APOA1-AS11116837697CT
rs67110162239952760526C2orf43umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.0023670322012NA220923592CA
rs67201731517535264240ABCG5umls:C0524620BeFreeLow serum cholesterol and cholesterol absorption were linked to the D19H polymorphism of the ABCG8 gene, and characteristics of the insulin resistance syndrome in men were linked with the Q604E polymorphism of the ABCG5 gene.0.0002714422004DYNC2LI1;ABCG5243813262GC
rs67201731517535264241ABCG8umls:C0524620BeFreeLow serum cholesterol and cholesterol absorption were linked to the D19H polymorphism of the ABCG8 gene, and characteristics of the insulin resistance syndrome in men were linked with the Q604E polymorphism of the ABCG5 gene.0.0029099162004DYNC2LI1;ABCG5243813262GC
rs67201731517535264241ABCG8umls:C3714619BeFreeLow serum cholesterol and cholesterol absorption were linked to the D19H polymorphism of the ABCG8 gene, and characteristics of the insulin resistance syndrome in men were linked with the Q604E polymorphism of the ABCG5 gene.0.0002714422004DYNC2LI1;ABCG5243813262GC
rs67201731517535264240ABCG5umls:C3714619BeFreeLow serum cholesterol and cholesterol absorption were linked to the D19H polymorphism of the ABCG8 gene, and characteristics of the insulin resistance syndrome in men were linked with the Q604E polymorphism of the ABCG5 gene.0.0002714422004DYNC2LI1;ABCG5243813262GC
rs67354822399527338APOBumls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1319111052012APOB221014672GA
rs67354822399527338APOBumls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1319111052012APOB221014672GA
rs6923761253765282740GLP1Rumls:C0524620BeFreeRelation of the rs6923761 gene variant in glucagon-like peptide 1 receptor to metabolic syndrome in obese subjects.0.0005428842014GLP1R639066296GA,C
rs6962171610884251738GHRLumls:C0524620BeFreeLarge-scale studies of the Leu72Met polymorphism of the ghrelin gene in relation to the metabolic syndrome and associated quantitative traits.0.0087297472005GHRL;GHRLOS310289773GT
rs713880324269186132789GNPDA2umls:C0524620BeFreeOf 11 SNPs, GNPDA2 rs10938397, BDNF rs6265, and FAIM2 rs7138803 were nominally associated with risk of MetS (GNPDA2 rs10938397: odds ratio (OR)=1.21, 95% confidence interval (CI)=1.04-1.40, P=0.016; BDNF rs6265: OR=1.19, 95% CI=1.03-1.39, P=0.021; FAIM2 rs7138803: OR=1.20, 95% CI=1.02-1.40, P=0.025); genetic risk score (GRS) was significantly associated with risk of MetS (OR=1.09, 95% CI=1.04-1.15, P=5.26×10(-4)).0.0005428842013NA1249853685GA
rs7154455220116272100ESR2umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0034527992012ESR21464269942GC
rs7154455220116272099ESR1umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0069055992012ESR21464269942GC
rs72046092174185879068FTOumls:C0524620BeFreeThe C allele of the rs7204609 polymorphism in the FTO gene increased the chance for the presence of MetS, especially central obesity, and microalbuminuria, independently of energy and nutrient intakes in this sample of type 2 diabetic patients from Southern Brazil.0.1400979682012FTO1653799693TC
rs7384092494777080339PNPLA3umls:C0524620BeFreeAge and HOMA-IR were positive independent predictors of metabolic syndrome, while a negative independent association was found between metabolic syndrome and the homozygotes PNPLA3 I148M variant.0.0066341572014PNPLA32243928847CG
rs7384092593972080339PNPLA3umls:C0524620BeFreeThe PNPLA3 rs738409 polymorphism is associated already in youths with increased ALT, and is more frequent in obese with MetS of all ages.0.0066341572015PNPLA32243928847CG
rs7384092562471280339PNPLA3umls:C0524620BeFreeFirst, we analyze the impact of demographic and ethnic characteristics of the PNPLA3 I148M variant and the presence of metabolic syndrome on the association between PNPLA3 I148M and NAFLD.0.0066341572014PNPLA32243928847CG
rs7532692411718687948CD36umls:C3714619BeFreeAssociation of the Pro90Ser CD36 mutation with elevated free fatty acid concentrations but not with insulin resistance syndrome in Japanese.0.0002714422001CD36780656687CT
rs7532692411718687948CD36umls:C0524620BeFreeAssociation of the Pro90Ser CD36 mutation with elevated free fatty acid concentrations but not with insulin resistance syndrome in Japanese.0.0893485762001CD36780656687CT
rs757584021393584338APOBumls:C0524620BeFreeFurthermore, our transcript analyses of adipose RNA samples from 175 subjects in the Finnish Metabolic Syndrome in Men study indicate that rs7575840 alters expression of APOB (P=1.13×10(-10)) and a regional noncoding RNA (BU630349) (P=7.86×10(-6)) in adipose tissue.0.1319111052011NA221050618GT
rs767455172007725054SERPINE1umls:C0524620BeFreeThe aim of this study was to investigate the influence of polymorphism A36G of the TNF receptor 1 (TNFRSF1A +36A/G) on plasma concentrations of PAI-1 in 163 obese (31 with the metabolic syndrome, MetS) and 150 lean, healthy women.0.016330122007TNFRSF1A126341779TC
rs767455172007727124TNFumls:C0524620BeFreeThe aim of this study was to investigate the influence of polymorphism A36G of the TNF receptor 1 (TNFRSF1A +36A/G) on plasma concentrations of PAI-1 in 163 obese (31 with the metabolic syndrome, MetS) and 150 lean, healthy women.0.0220740062007TNFRSF1A126341779TC
rs767455172007727132TNFRSF1Aumls:C0524620BeFreeThe aim of this study was to investigate the influence of polymorphism A36G of the TNF receptor 1 (TNFRSF1A +36A/G) on plasma concentrations of PAI-1 in 163 obese (31 with the metabolic syndrome, MetS) and 150 lean, healthy women.0.0005428842007TNFRSF1A126341779TC
rs7757956220116272099ESR1umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0069055992012ESR16151996005TA
rs7757956220116272100ESR2umls:C0524620BeFreeTo investigate genetic single nucleotide polymorphisms (SNPs) in estrogen receptor-α (ERα) (ESR1, rs2234693, rs1801132, rs7757956 and rs2813544) and ERβ (ESR2, rs3020450, rs7154455 and rs4986938) genes and relate them to the adverse effects lipodystrophy, dyslipidemia and metabolic syndrome as well as to differences in their prevalence between sexes in HIV-infected individuals on HAART.0.0034527992012ESR16151996005TA
rs780093213860852646GCKRumls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1287297472011GCKR227519736TC
rs780094223995272646GCKRumls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1287297472012GCKR227518370TC
rs780094223995272646GCKRumls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1287297472012GCKR227518370TC
rs7825902239952757223SMEK2umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.0023670322012SMEK2255616277CT
rs7841189223995274023LPLumls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1396310292012NA819987865CT
rs7903146217496083569IL6umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1437125892011TCF7L210112998590CT
rs7903146217496086934TCF7L2umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1290011892011TCF7L210112998590CT
rs7903146188531346934TCF7L2umls:C0524620BeFreePolymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004).0.1290011892008TCF7L210112998590CT
rs7903146191416986934TCF7L2umls:C0524620BeFreeIn summary, high (n-6) PUFA intakes (> or = 6.62% of energy intake) were associated with atherogenic dyslipidemia in carriers of the minor T allele at the TCF7L2 rs7903146 SNP and may predispose them to MetS, diabetes, and cardiovascular disease.0.1290011892009TCF7L210112998590CT
rs7903146215432004149MAXumls:C0524620BeFreeThis study investigated the relationship between the TCF7L2 rs7903146 polymorphism, insulin sensitivity/resistance and MetS in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n=1754) and determined potential interactions with dietary fat intake.0.0013572092012TCF7L210112998590CT
rs790314621749608345APOC3umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1007267282011TCF7L210112998590CT
rs790314621749608116519APOA5umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1712927162011TCF7L210112998590CT
rs7903146206941486934TCF7L2umls:C0524620GWASCATA genome-wide association study of the metabolic syndrome in Indian Asian men.0.1290011892010TCF7L210112998590CT
rs7965413256469617450VWFumls:C0524620BeFreeIdentification of an interaction between VWF rs7965413 and platelet count as a novel risk marker for metabolic syndrome: an extensive search of candidate polymorphisms in a case-control study.0.0005428842014VWF126125723CT
rs79654132564696123026MYO16umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014VWF126125723CT
rs796541325646961116519APOA5umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.1712927162014VWF126125723CT
rs7965413256469614036LRP2umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014VWF126125723CT
rs7965413256469618660IRS2umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0039956832014VWF126125723CT
rs79654132564696123158TBC1D9umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0002714422014VWF126125723CT
rs7965413256469617350UCP1umls:C0524620BeFreeOf these SNPs, five SNPs were significantly associated with MetS (P < 0.05): LRP2 rs2544390, rs1800592 between UCP1 and TBC1D9, APOA5 rs662799, VWF rs7965413, and rs1411766 between MYO16 and IRS2.0.0039956832014VWF126125723CT
rs80606862239952723644EDC4umls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1223670322012EDC41667877614TC
rs80606862239952723644EDC4umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1223670322012EDC41667877614TC
rs916829258673986616SNAP25umls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0026384742016ABCC81117418926AG
rs916829258673983482IGF2Rumls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0002714422016ABCC81117418926AG
rs916829258673986833ABCC8umls:C0524620BeFreeFor the SNP genotypes of rs362551 (SNAP25), rs3818569 (RXRG), rs1479355, rs1570070 (IGF2R), and rs916829 (ABCC8), heterozygotes showed a lower risk of MetS compared with the reference group.0.0026384742016ABCC81117418926AG
rs92825411800376019ABCA1umls:C0524620BeFreeThe ATP-binding cassette transporter A1 (ABCA1) R230C variant is associated with low HDL cholesterol levels, obesity, and the metabolic syndrome in Mexican-Mestizos.0.1258198312008ABCA19104858554GA
rs964184223995278882ZPR1umls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1252769482012ZPR111116778201GC
rs96418422399527335APOA1umls:C0524620BeFreeA previously known lipid locus, APOA1/C3/A4/A5 gene cluster region (SNP rs964184), was associated with MetS in all 4 study samples (P=7.23×10(-9) in meta-analysis).0.0882628082012ZPR111116778201GC
rs964184223995278882ZPR1umls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1252769482012ZPR111116778201GC
rs9939224213860851071CETPumls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.1416506752011CETP1656968820TG
rs9939224213860851071CETPumls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.1416506752011CETP1656968820TG
rs99396091833920479068FTOumls:C0524620GAD[Association between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample.]0.1400979682008FTO1653786615TA
rs99396092467514879068FTOumls:C0524620BeFreeThe FTO gene polymorphism (rs9939609) is associated with metabolic syndrome in morbidly obese subjects from southern Italy.0.1400979682014FTO1653786615TA
rs993960921749608116519APOA5umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1712927162011FTO1653786615TA
rs993960921749608345APOC3umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1007267282011FTO1653786615TA
rs99396092349027879068FTOumls:C0524620BeFreeThe FTO gene polymorphism (rs9939609) was found to be associated with increased insulin resistance, insulin and triglyceride levels in obese females with TT variant and without metabolic syndrome.0.1400979682013FTO1653786615TA
rs9939609188531346934TCF7L2umls:C0524620BeFreePolymorphisms in TCF7L2 (rs7903146, OR 1.10, 95% CI 1.04-1.17, p = 0.00097), FTO (rs9939609, OR 1.08, 95% CI 1.02-1.14, p = 0.0065), WFS1 (rs10010131, OR 1.07, 95% CI 1.02-1.13, p = 0.0078) and IGF2BP2 (rs4402960, OR 1.07, 95% CI 1.01-1.13, p = 0.021) predicted the development of at least three components of the metabolic syndrome in both univariate and multivariate analysis; in the case of TCF7L2, WFS1 and IGF2BP this was due to their association with hyperglycaemia (p < 0.00001, p = 0.0033 and p = 0.027, respectively) and for FTO it was due to its association with obesity (p = 0.004).0.1290011892008FTO1653786615TA
rs9939609217496086934TCF7L2umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1290011892011FTO1653786615TA
rs99396092231101579068FTOumls:C0524620BeFreeCommon variant (rs9939609) in the FTO gene is associated with metabolic syndrome.0.1400979682012FTO1653786615TA
rs9939609234902783630INSumls:C0524620BeFreeThe FTO gene polymorphism (rs9939609) was found to be associated with increased insulin resistance, insulin and triglyceride levels in obese females with TT variant and without metabolic syndrome.0.1669594442013FTO1653786615TA
rs99396092245739479068FTOumls:C0524620BeFreeIn conclusion, FTO rs9939609 was associated with obesity measures, especially in those with the MetS, which was further exacerbated by high dietary SFA intake at baseline and 7.5 y later.0.1400979682012FTO1653786615TA
rs9939609217496083569IL6umls:C0524620BeFreeThe minor allele of rs9939609 (FTO), rs7903146 (TCF7L2), C56G (APOA5), T1131C (APOA5), C482T (APOC3), C455T (APOC3) and 174G>C (IL6) were more prevalent in subjects with MetS, whereas the minor allele of Taq-1B (CETP) was less prevalent in subjects with the MetS.0.1437125892011FTO1653786615TA
rs99396091833920479068FTOumls:C0524620BeFreeAssociation between the FTO rs9939609 polymorphism and the metabolic syndrome in a non-Caucasian multi-ethnic sample.0.1400979682008FTO1653786615TA
rs99401282239952779068FTOumls:C0524620GWASCATGenome-wide screen for metabolic syndrome susceptibility Loci reveals strong lipid gene contribution but no evidence for common genetic basis for clustering of metabolic syndrome traits.0.1400979682012FTO1653766842GA
rs99401282239952779068FTOumls:C0524620GAD[Our findings suggest that genes from lipid metabolism pathways have the key role in the genetic background of MetS. We found little evidence for pleiotropy linking dyslipidemia and obesity to the other MetS component traits, such as hypertension and gluco]0.1400979682012FTO1653766842GA
rs997509189408785167ENPP1umls:C0524620BeFreeEffect of the rs997509 polymorphism on the association between ectonucleotide pyrophosphatase phosphodiesterase 1 and metabolic syndrome and impaired glucose tolerance in childhood obesity.0.0145495792009ENPP16131846837CT
rs99872892138608579660PPP1R3Bumls:C0524620GAD[Qualitative and quantitative pleiotropic tests on pairs of traits indicate that a small portion of the covariation in these traits can be explained by the reported common genetic variants.]0.0023670322011LOC15727389325848AG
rs998728921386085157273LOC157273umls:C0524620GWASCATA bivariate genome-wide approach to metabolic syndrome: STAMPEED consortium.0.122011LOC15727389325848AG
rs9997745201768583630INSumls:C0524620BeFreeGG homozygotes for rs9997745 had increased MetS risk {odds ratio (OR) 1.90 [confidence interval (CI) 1.15, 3.13]; P = 0.01}, displayed elevated fasting glucose (P = 0.001) and insulin concentrations (P = 0.002) and increased insulin resistance (P = 0.03) relative to the A allele carriers.0.1669594442010ACSL14184816689GA
rs9997745201768584149MAXumls:C0524620BeFreeWe investigated the relationship between ACSL1 polymorphisms (rs4862417, rs6552828, rs13120078, rs9997745, and rs12503643) and MetS risk and determined potential interactions with dietary fat in the LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1,754).0.0013572092010ACSL14184816689GA
GWASdb Annotation(Total Genotypes:0)
(Waiting for update.)
GWASdb Snp Trait(Total Genotypes:0)
(Waiting for update.)
Mapped by lexical matching(Total Items:0)
(Waiting for update.)
Mapped by homologous gene(Total Items:0)
(Waiting for update.)
Disease ID 440
Disease metabolic syndrome x
Case(Waiting for update.)